https://trial.medpath.com/news/studying-a-culturally-tailored-anti-inflammatory-diet-s-impact-on-hispanic-latinx-patients 2024-10-04T16:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/studying-a-culturally-tailored-anti-inflammatory-diet-s-impact-on-hispanic-latinx-patients 2024-10-04T16:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-cognition-announces-executive-shake-up-drug-approval-tipranks-com 2024-10-04T16:40:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-cognition-announces-executive-shake-up-drug-approval-tipranks-com 2024-10-04T16:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/an-alzheimer-s-drugmaker-is-accused-of-data-manipulation-should-its-trials-be-stopped 2024-10-04T16:37:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-alzheimer-s-drugmaker-is-accused-of-data-manipulation-should-its-trials-be-stopped 2024-10-04T16:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-n-v-advances-in-clinical-development-of-novel-therapies-for-solid-and-liquid-tumors 2024-10-04T16:35:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/affimed-n-v-advances-in-clinical-development-of-novel-therapies-for-solid-and-liquid-tumors 2024-10-04T16:35:04+00:00 weekly 0.7 https://trial.medpath.com/news/magic-g1-study-provides-updated-findings-with-mtx110-in-recurrent-glioblastoma 2024-10-04T16:09:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/magic-g1-study-provides-updated-findings-with-mtx110-in-recurrent-glioblastoma 2024-10-04T16:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/pen-bay-waldo-expand-cardiac-rehab-offerings-mainehealth 2024-10-04T16:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pen-bay-waldo-expand-cardiac-rehab-offerings-mainehealth 2024-10-04T16:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/highlights-in-non-prostate-gu-oncology-from-esmo-2024-ignacio-duran-urotoday 2024-10-04T16:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highlights-in-non-prostate-gu-oncology-from-esmo-2024-ignacio-duran-urotoday 2024-10-04T16:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-receives-usfda-final-approval-for-alcaftadine-ophthalmic-solution-0-25-otc 2024-10-04T15:53:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-receives-usfda-final-approval-for-alcaftadine-ophthalmic-solution-0-25-otc 2024-10-04T15:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/chronic-urticaria-competitive-landscape-assessment-2024-globenewswire 2024-10-04T15:47:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chronic-urticaria-competitive-landscape-assessment-2024-globenewswire 2024-10-04T15:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/variation-in-opioid-agonist-dosing-in-clinical-trials-by-race-and-ethnicity-jama-network 2024-10-04T15:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/variation-in-opioid-agonist-dosing-in-clinical-trials-by-race-and-ethnicity-jama-network 2024-10-04T15:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/lanzatech-to-produce-30000-tonnes-of-microbial-protein-per-annum-the-fish-site 2024-10-04T15:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lanzatech-to-produce-30000-tonnes-of-microbial-protein-per-annum-the-fish-site 2024-10-04T15:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/vividion-continues-to-teach-covalent-compounds-new-tricks 2024-10-04T15:20:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vividion-continues-to-teach-covalent-compounds-new-tricks 2024-10-04T15:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/case-report-allogeneic-culture-expanded-bone-marrow-derived-mesenchymal-stem-cells-for 2024-10-04T15:04:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/case-report-allogeneic-culture-expanded-bone-marrow-derived-mesenchymal-stem-cells-for 2024-10-04T15:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/myeloproliferative-neoplasms-treatment-new-insights-hematology-advisor 2024-10-04T15:02:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myeloproliferative-neoplasms-treatment-new-insights-hematology-advisor 2024-10-04T15:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/tiumbio-announces-first-patient-dosed-in-phase-2-clinical-trial-of-oral-immuno-oncology 2024-10-04T15:01:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiumbio-announces-first-patient-dosed-in-phase-2-clinical-trial-of-oral-immuno-oncology 2024-10-04T15:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/amazing-trial-shows-drug-combination-stops-lung-cancer-advancing-for-longer 2024-10-04T14:51:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amazing-trial-shows-drug-combination-stops-lung-cancer-advancing-for-longer 2024-10-04T14:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-companies-consider-asset-sales-amid-us-biosecure-act-pressure 2024-10-04T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wuxi-companies-consider-asset-sales-amid-us-biosecure-act-pressure 2024-10-04T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-stock-jumps-as-lung-cancer-drug-placed-on-fda-fast-track 2024-10-04T14:14:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-therapeutics-stock-jumps-as-lung-cancer-drug-placed-on-fda-fast-track 2024-10-04T14:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-16-new-cancer-treatments-as-global-cancer-rates-skyrocket-kilgore-news-herald 2024-10-04T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-16-new-cancer-treatments-as-global-cancer-rates-skyrocket-kilgore-news-herald 2024-10-04T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/indoco-remedies-receives-u-s-fda-approval-for-generic-cetirizine-tablets 2024-10-04T13:44:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indoco-remedies-receives-u-s-fda-approval-for-generic-cetirizine-tablets 2024-10-04T13:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-compound-analysis-of-medical-device-clinical-trials-registered-in-africa-on-clinicaltrials-gov 2024-10-04T13:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-compound-analysis-of-medical-device-clinical-trials-registered-in-africa-on-clinicaltrials-gov 2024-10-04T13:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/emavusertib-focused-research-is-poised-to-expand-the-pcnsl-treatment-paradigm 2024-10-04T13:24:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emavusertib-focused-research-is-poised-to-expand-the-pcnsl-treatment-paradigm 2024-10-04T13:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/turkey-brazil-emerging-as-clinical-trial-destinations-for-cancer-drugs-biospace 2024-10-04T13:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/turkey-brazil-emerging-as-clinical-trial-destinations-for-cancer-drugs-biospace 2024-10-04T13:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/h-c-wainwright-keeps-buy-rating-on-summit-therapeutics-stock-highlighting-fast-track-designation 2024-10-04T13:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/h-c-wainwright-keeps-buy-rating-on-summit-therapeutics-stock-highlighting-fast-track-designation 2024-10-04T13:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-engages-syneos-health-as-cro-for-its-phase-ii-oncology-trial 2024-10-04T12:50:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-engages-syneos-health-as-cro-for-its-phase-ii-oncology-trial 2024-10-04T12:50:22+00:00 weekly 0.7 https://trial.medpath.com/news/the-first-six-months-of-the-2024-voluntary-scheme 2024-10-04T12:38:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-first-six-months-of-the-2024-voluntary-scheme 2024-10-04T12:38:48+00:00 weekly 0.7 https://trial.medpath.com/news/trevi-therapeutics-provides-update-on-haduvio-s-clinical-development-program 2024-10-04T12:38:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trevi-therapeutics-provides-update-on-haduvio-s-clinical-development-program 2024-10-04T12:38:43+00:00 weekly 0.7 https://trial.medpath.com/news/biodexa-provides-update-on-progression-free-and-overall-globenewswire 2024-10-04T12:34:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biodexa-provides-update-on-progression-free-and-overall-globenewswire 2024-10-04T12:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-announces-participation-at-the-4th-annual-needham-private-biotech 2024-10-04T12:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sapience-therapeutics-announces-participation-at-the-4th-annual-needham-private-biotech 2024-10-04T12:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-selection-landscape-evolves-for-egfr-nsclc-with-new-therapeutic-options 2024-10-04T12:18:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-selection-landscape-evolves-for-egfr-nsclc-with-new-therapeutic-options 2024-10-04T12:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/avistone-announces-updates-on-ans014004-yahoo-finance 2024-10-04T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avistone-announces-updates-on-ans014004-yahoo-finance 2024-10-04T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/creation-of-de-novo-cryptic-splicing-for-als-and-ftd-precision-medicine-pubmed 2024-10-04T11:51:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/creation-of-de-novo-cryptic-splicing-for-als-and-ftd-precision-medicine-pubmed 2024-10-04T11:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/oxcia-is-focusing-the-development-of-oxc-101-on-hematological-cancers-cision-news 2024-10-04T11:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxcia-is-focusing-the-development-of-oxc-101-on-hematological-cancers-cision-news 2024-10-04T11:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/hepatocellular-carcinoma-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-10-04T11:30:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hepatocellular-carcinoma-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-10-04T11:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/pompe-disease-clinical-trials-2024-updates-ema-pdma-fda-openpr-com 2024-10-04T11:27:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pompe-disease-clinical-trials-2024-updates-ema-pdma-fda-openpr-com 2024-10-04T11:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/turkish-nobel-scientist-aziz-sancar-s-brain-cancer-breakthrough-enters-human-trials 2024-10-04T11:19:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/turkish-nobel-scientist-aziz-sancar-s-brain-cancer-breakthrough-enters-human-trials 2024-10-04T11:19:59+00:00 weekly 0.7 https://trial.medpath.com/news/anti-cd70-antibodies-clinical-trials-fda-approval-cd70-globenewswire 2024-10-04T11:16:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-cd70-antibodies-clinical-trials-fda-approval-cd70-globenewswire 2024-10-04T11:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/global-lag-3-antibody-fda-approval-clinical-trials-lag-3-globenewswire 2024-10-04T11:16:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-lag-3-antibody-fda-approval-clinical-trials-lag-3-globenewswire 2024-10-04T11:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/airdrie-family-seeks-support-for-potential-life-saving-drug-trial-in-the-u-s 2024-10-04T11:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/airdrie-family-seeks-support-for-potential-life-saving-drug-trial-in-the-u-s 2024-10-04T11:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-quantisnow 2024-10-04T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-quantisnow 2024-10-04T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-exact-sciences-cologuard-plus-test-setting-a-new-benchmark-in-non 2024-10-04T10:10:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-exact-sciences-cologuard-plus-test-setting-a-new-benchmark-in-non 2024-10-04T10:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-vaccine-s-protection-wanes-within-1-year-boosters-needed 2024-10-04T09:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpox-vaccine-s-protection-wanes-within-1-year-boosters-needed 2024-10-04T09:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/abl-bio-announces-clinical-collaboration-to-evaluate-abl103-in-combination-with-biospace 2024-10-04T08:07:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abl-bio-announces-clinical-collaboration-to-evaluate-abl103-in-combination-with-biospace 2024-10-04T08:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/mckesson-launches-inspirogene-to-revolutionize-cell-and-gene-therapy-commercialization 2024-10-04T06:05:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mckesson-launches-inspirogene-to-revolutionize-cell-and-gene-therapy-commercialization 2024-10-04T06:05:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-dual-approval-for-amivantamab-in-non-small-cell-lung-cancer-treatment 2024-10-04T05:52:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-dual-approval-for-amivantamab-in-non-small-cell-lung-cancer-treatment 2024-10-04T05:52:19+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-resubmits-new-drug-application-for-reproxalap-for-the-treatment-of-dry 2024-10-04T05:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-resubmits-new-drug-application-for-reproxalap-for-the-treatment-of-dry 2024-10-04T05:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-treatment-advances-drive-90-survival-rate-in-early-stage-disease-expert-highlights-progress 2024-10-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-cancer-treatment-advances-drive-90-survival-rate-in-early-stage-disease-expert-highlights-progress 2024-10-04T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-mab-policies-do-not-set-precedent-for-accelerated-approval-cms-s-former-cmo-says 2024-10-04T04:24:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-mab-policies-do-not-set-precedent-for-accelerated-approval-cms-s-former-cmo-says 2024-10-04T04:24:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-presurgical-postsurgical-opdivo-for-nsclc-cure-today 2024-10-04T03:47:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-presurgical-postsurgical-opdivo-for-nsclc-cure-today 2024-10-04T03:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-provides-update-on-stage-1-cohorts-in-pivotal-phase-1-2-3-cyprus2-study 2024-10-04T03:03:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-provides-update-on-stage-1-cohorts-in-pivotal-phase-1-2-3-cyprus2-study 2024-10-04T03:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/international-experts-to-gather-for-als-symposium-in-chicago-news-medical 2024-10-04T02:42:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-experts-to-gather-for-als-symposium-in-chicago-news-medical 2024-10-04T02:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/recordati-acquires-global-rights-to-sanofi-s-cad-treatment-enjaymo-in-825m-deal 2024-10-04T02:31:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recordati-acquires-global-rights-to-sanofi-s-cad-treatment-enjaymo-in-825m-deal 2024-10-04T02:31:06+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-promising-phase-i-results-for-parkinson-s-disease-cell-therapy-regmednet 2024-10-04T01:31:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-weekly-promising-phase-i-results-for-parkinson-s-disease-cell-therapy-regmednet 2024-10-04T01:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-achieves-complete-response-in-estrella-immunopharma-s-trial-for-cgtlive-r 2024-10-04T01:27:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-achieves-complete-response-in-estrella-immunopharma-s-trial-for-cgtlive-r 2024-10-04T01:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-toripalimab-plus-axitinib-for-clear-cell-renal-cell-carcinoma-with-inferior-vena 2024-10-04T01:15:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-toripalimab-plus-axitinib-for-clear-cell-renal-cell-carcinoma-with-inferior-vena 2024-10-04T01:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/anvs-annovis-bio-inc-latest-stock-news-market-updates 2024-10-04T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anvs-annovis-bio-inc-latest-stock-news-market-updates 2024-10-04T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/abivax-announces-first-patient-enrolled-in-enhance-cd-the-phase-2b-trial-of-biospace 2024-10-04T00:40:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abivax-announces-first-patient-enrolled-in-enhance-cd-the-phase-2b-trial-of-biospace 2024-10-04T00:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/allegheny-general-hospital-among-nation-s-top-enrollment-sites-for-clinical-trial-exploring 2024-10-04T00:31:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allegheny-general-hospital-among-nation-s-top-enrollment-sites-for-clinical-trial-exploring 2024-10-04T00:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-ovarian-cancer-vaccine-being-developed-in-uk-the-independent 2024-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-ovarian-cancer-vaccine-being-developed-in-uk-the-independent 2024-10-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-awarded-up-to-2-6-million-grant-from-globenewswire 2024-10-03T23:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palvella-therapeutics-awarded-up-to-2-6-million-grant-from-globenewswire 2024-10-03T23:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/gastroenterology-month-in-review-september-2024-hcplive 2024-10-03T23:03:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastroenterology-month-in-review-september-2024-hcplive 2024-10-03T23:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/cellprothera-begins-long-term-observational-study-to-demonstrate-safety-and-efficacy-of 2024-10-03T22:53:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellprothera-begins-long-term-observational-study-to-demonstrate-safety-and-efficacy-of 2024-10-03T22:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-uva-health-tested-lung-cancer-treatment-wvir 2024-10-03T22:45:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-uva-health-tested-lung-cancer-treatment-wvir 2024-10-03T22:45:20+00:00 weekly 0.7 https://trial.medpath.com/news/steap1-targeted-t-cell-engager-demonstrates-efficacy-in-mcrpc-patients-william-kevin-kelly 2024-10-03T22:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/steap1-targeted-t-cell-engager-demonstrates-efficacy-in-mcrpc-patients-william-kevin-kelly 2024-10-03T22:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-program-receives-platinum-award-for-patient-participation-in-cancer-research 2024-10-03T21:30:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-program-receives-platinum-award-for-patient-participation-in-cancer-research 2024-10-03T21:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/investigation-of-serum-neurofilament-light-chain-as-a-biomarker-in-fabry-disease-nature 2024-10-03T20:56:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigation-of-serum-neurofilament-light-chain-as-a-biomarker-in-fabry-disease-nature 2024-10-03T20:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/nsf-nih-and-fda-support-research-in-digital-twin-technology-for-biomedical-applications 2024-10-03T20:53:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nsf-nih-and-fda-support-research-in-digital-twin-technology-for-biomedical-applications 2024-10-03T20:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/dr-girard-on-pros-from-the-luminosity-trial-in-c-met-overexpressing-nsclc-onclive 2024-10-03T19:46:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-girard-on-pros-from-the-luminosity-trial-in-c-met-overexpressing-nsclc-onclive 2024-10-03T19:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/ge-healthcare-s-mim-software-wins-fda-clearance-for-monte-carlo-dosimetry-massdevice 2024-10-03T19:36:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ge-healthcare-s-mim-software-wins-fda-clearance-for-monte-carlo-dosimetry-massdevice 2024-10-03T19:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/future-of-oral-small-molecule-drugs-addressing-potential-in-multiple-sclerosis 2024-10-03T19:04:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/future-of-oral-small-molecule-drugs-addressing-potential-in-multiple-sclerosis 2024-10-03T19:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/grand-rounds-september-27-2024-azithromycin-for-childhood-mortality-rethinking-clinical-trials 2024-10-03T18:49:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grand-rounds-september-27-2024-azithromycin-for-childhood-mortality-rethinking-clinical-trials 2024-10-03T18:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trial-fedratinib-reduces-spleen-size-in-ruxolitinib-refractory-myelofibrosis 2024-10-03T18:43:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-trial-fedratinib-reduces-spleen-size-in-ruxolitinib-refractory-myelofibrosis 2024-10-03T18:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-proposes-phased-launch-of-obesity-injection-pf-media 2024-10-03T18:36:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-england-proposes-phased-launch-of-obesity-injection-pf-media 2024-10-03T18:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/stemcyte-s-hpc-cord-blood-receives-rmat-designation-for-long-covid-19-treatment 2024-10-03T18:13:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stemcyte-s-hpc-cord-blood-receives-rmat-designation-for-long-covid-19-treatment 2024-10-03T18:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/artax-biopharma-to-present-first-in-class-nck-modulator-mechanism-of-action-and-phase-1 2024-10-03T18:08:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artax-biopharma-to-present-first-in-class-nck-modulator-mechanism-of-action-and-phase-1 2024-10-03T18:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/recent-clinical-data-confirms-significantly-improved-predictive-power-of-evaxion-s-ai 2024-10-03T18:07:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-clinical-data-confirms-significantly-improved-predictive-power-of-evaxion-s-ai 2024-10-03T18:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma 2024-10-03T18:05:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma 2024-10-03T18:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/ec-approves-daiichi-sankyo-s-vanflyta-for-acute-myeloid-leukaemia-msn 2024-10-03T17:55:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ec-approves-daiichi-sankyo-s-vanflyta-for-acute-myeloid-leukaemia-msn 2024-10-03T17:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-amphix-bio-s-bone-regeneration-product 2024-10-03T17:52:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-amphix-bio-s-bone-regeneration-product 2024-10-03T17:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/therivatm-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee 2024-10-03T17:45:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therivatm-biologics-announces-positive-outcome-of-data-and-safety-monitoring-committee 2024-10-03T17:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-trial-data-boosts-case-for-newer-drug-resistant-tb-regimens-cidrap 2024-10-03T17:19:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-trial-data-boosts-case-for-newer-drug-resistant-tb-regimens-cidrap 2024-10-03T17:19:28+00:00 weekly 0.7 https://trial.medpath.com/news/ketamine-pills-could-finally-offer-depression-breakthrough-miriam-stoppard-mirror-online 2024-10-03T17:14:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ketamine-pills-could-finally-offer-depression-breakthrough-miriam-stoppard-mirror-online 2024-10-03T17:14:21+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-therapy-nd0612-reduces-off-time-increases-on-time-after-a-year 2024-10-03T17:05:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-therapy-nd0612-reduces-off-time-increases-on-time-after-a-year 2024-10-03T17:05:15+00:00 weekly 0.7 https://trial.medpath.com/news/virtual-family-centered-rounds-help-parents-support-their-child-s-care-uc-davis-health 2024-10-03T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virtual-family-centered-rounds-help-parents-support-their-child-s-care-uc-davis-health 2024-10-03T17:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/alfasigma-receives-green-light-to-sell-jyseleca-in-europe-born2invest 2024-10-03T16:32:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alfasigma-receives-green-light-to-sell-jyseleca-in-europe-born2invest 2024-10-03T16:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/nucleos-t-ide-analogs-to-treat-patients-with-positive-hepatitis-b-virus-deoxyribonucleic-acid 2024-10-03T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nucleos-t-ide-analogs-to-treat-patients-with-positive-hepatitis-b-virus-deoxyribonucleic-acid 2024-10-03T16:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/after-40m-settlement-alzheimer-s-drug-under-scrutiny-as-human-trials-proceed 2024-10-03T16:21:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-40m-settlement-alzheimer-s-drug-under-scrutiny-as-human-trials-proceed 2024-10-03T16:21:22+00:00 weekly 0.7 https://trial.medpath.com/news/assessment-of-antitachycardia-pacing-in-primary-prevention-patients-jama-network 2024-10-03T16:20:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assessment-of-antitachycardia-pacing-in-primary-prevention-patients-jama-network 2024-10-03T16:20:40+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-dll3-targeted-therapies-demonstrate-efficacy-in-neuroendocrine-prostate-cancer 2024-10-03T16:13:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-dll3-targeted-therapies-demonstrate-efficacy-in-neuroendocrine-prostate-cancer 2024-10-03T16:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/veracyte-s-rna-genetic-test-predicts-black-men-s-aggressive-prostate-cancer 2024-10-03T16:11:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veracyte-s-rna-genetic-test-predicts-black-men-s-aggressive-prostate-cancer 2024-10-03T16:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/six-biotechs-driving-progress-in-duchenne-muscular-dystrophy-labiotech-eu 2024-10-03T15:59:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/six-biotechs-driving-progress-in-duchenne-muscular-dystrophy-labiotech-eu 2024-10-03T15:59:11+00:00 weekly 0.7 https://trial.medpath.com/news/can-eye-drops-replace-surgery-for-curing-cataracts-theu 2024-10-03T15:55:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-eye-drops-replace-surgery-for-curing-cataracts-theu 2024-10-03T15:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-nivolumab-vs-placebo-in-localized-renal-cell-carcinoma-at-high-risk-of 2024-10-03T15:53:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-nivolumab-vs-placebo-in-localized-renal-cell-carcinoma-at-high-risk-of 2024-10-03T15:53:29+00:00 weekly 0.7 https://trial.medpath.com/news/autologous-vs-allogeneic-stem-cell-transplantation-in-younger-patients-with-peripheral-t 2024-10-03T15:50:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autologous-vs-allogeneic-stem-cell-transplantation-in-younger-patients-with-peripheral-t 2024-10-03T15:50:31+00:00 weekly 0.7 https://trial.medpath.com/news/calcium-carbonate-supplementation-for-the-prevention-of-preeclampsia-in-high-risk-pregnant-women 2024-10-03T15:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calcium-carbonate-supplementation-for-the-prevention-of-preeclampsia-in-high-risk-pregnant-women 2024-10-03T15:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/convalescent-plasma-might-have-saved-thousands-more-lives-during-covid-pandemic 2024-10-03T15:32:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/convalescent-plasma-might-have-saved-thousands-more-lives-during-covid-pandemic 2024-10-03T15:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-therapy-might-repair-vision-robbing-holes-in-retinas 2024-10-03T15:10:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-therapy-might-repair-vision-robbing-holes-in-retinas 2024-10-03T15:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/investigating-early-diagnosis-through-genomic-medicine-nhs-england 2024-10-03T15:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigating-early-diagnosis-through-genomic-medicine-nhs-england 2024-10-03T15:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-kerendia-demonstrates-success-in-phase-3-clinical-trials-for-treatment-of-heart-failure 2024-10-03T14:36:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-kerendia-demonstrates-success-in-phase-3-clinical-trials-for-treatment-of-heart-failure 2024-10-03T14:36:40+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-semaglutide-more-efficacious-than-other-fda-approved-drugs-for-weight-loss 2024-10-03T14:24:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-semaglutide-more-efficacious-than-other-fda-approved-drugs-for-weight-loss 2024-10-03T14:24:51+00:00 weekly 0.7 https://trial.medpath.com/news/peph-newsletter-october-2024-national-institute-of-environmental-health-sciences 2024-10-03T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/peph-newsletter-october-2024-national-institute-of-environmental-health-sciences 2024-10-03T14:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-versamune-hpv-vaccine-bolsters-responses-with-soc-pembrolizumab-in-onclive 2024-10-03T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-versamune-hpv-vaccine-bolsters-responses-with-soc-pembrolizumab-in-onclive 2024-10-03T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-testing-saved-my-life-illumina 2024-10-03T13:53:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomic-testing-saved-my-life-illumina 2024-10-03T13:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/mangorx-introduces-oral-tirzepatide-glp-1-receptor-agonist-for-advanced-weight-loss-solutions 2024-10-03T12:41:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mangorx-introduces-oral-tirzepatide-glp-1-receptor-agonist-for-advanced-weight-loss-solutions 2024-10-03T12:41:14+00:00 weekly 0.7 https://trial.medpath.com/news/elucid-scoops-fda-approval-for-ai-cardiovascular-risk-diagnostic-yahoo-finance 2024-10-03T12:32:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elucid-scoops-fda-approval-for-ai-cardiovascular-risk-diagnostic-yahoo-finance 2024-10-03T12:32:56+00:00 weekly 0.7 https://trial.medpath.com/news/resolution-therapeutics-announces-ps63-5-million-series-b-financing-and-chair-appointment 2024-10-03T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resolution-therapeutics-announces-ps63-5-million-series-b-financing-and-chair-appointment 2024-10-03T12:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of 2024-10-03T12:15:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-to-present-outcomes-data-through-42-months-from-the-open-label-extension-of 2024-10-03T12:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-completes-patient-enrolment-in-randomised-phase-ii-of-aipac-003-trial-in 2024-10-03T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-completes-patient-enrolment-in-randomised-phase-ii-of-aipac-003-trial-in 2024-10-03T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/major-alzheimer-s-breakthrough-as-experts-discover-double-whammy-drug-that-destroys 2024-10-03T12:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-alzheimer-s-breakthrough-as-experts-discover-double-whammy-drug-that-destroys 2024-10-03T12:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-jumps-4-on-us-fda-approves-anti-seizure-drug-worth-163-million 2024-10-03T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharma-jumps-4-on-us-fda-approves-anti-seizure-drug-worth-163-million 2024-10-03T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/new-jersey-biotech-reports-positive-survival-data-the-streetwise-reports 2024-10-03T11:17:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-jersey-biotech-reports-positive-survival-data-the-streetwise-reports 2024-10-03T11:17:40+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-announces-fda-removed-partial-clinical-hold-on-delpacibart 2024-10-03T11:15:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avidity-biosciences-announces-fda-removed-partial-clinical-hold-on-delpacibart 2024-10-03T11:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/validation-of-a-digital-pathology-based-mmai-model-in-oligometastatic-castration-sensitive 2024-10-03T11:09:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/validation-of-a-digital-pathology-based-mmai-model-in-oligometastatic-castration-sensitive 2024-10-03T11:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-ii-ca-nine-trial-of-tlx250-cdx-for-detection-of-recurrent 2024-10-03T11:07:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-ii-ca-nine-trial-of-tlx250-cdx-for-detection-of-recurrent 2024-10-03T11:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/eye-on-pharma-high-strength-trastuzumab-biosimilar-originator-coverage-removals 2024-10-03T11:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-on-pharma-high-strength-trastuzumab-biosimilar-originator-coverage-removals 2024-10-03T11:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/rwanda-to-kick-off-vaccine-and-therapeutic-clinical-trials-for-marbug-disease-in-several-weeks 2024-10-03T11:02:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rwanda-to-kick-off-vaccine-and-therapeutic-clinical-trials-for-marbug-disease-in-several-weeks 2024-10-03T11:02:44+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-nvax-stock-rises-19-after-fda-approval-for-updated-covid-19-vaccine 2024-10-03T10:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-nvax-stock-rises-19-after-fda-approval-for-updated-covid-19-vaccine 2024-10-03T10:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/could-lithium-supplements-ease-the-brain-fog-of-long-covid 2024-10-03T10:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-lithium-supplements-ease-the-brain-fog-of-long-covid 2024-10-03T10:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-zunveyl-for-alzheimer-s-symptoms-on-the-way-in-2025-being-patient 2024-10-03T10:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-zunveyl-for-alzheimer-s-symptoms-on-the-way-in-2025-being-patient 2024-10-03T10:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/datacc-by-dime-awarded-fda-grant-to-boost-use-of-sensor-based-digital-health 2024-10-03T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/datacc-by-dime-awarded-fda-grant-to-boost-use-of-sensor-based-digital-health 2024-10-03T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-invest-4-5bn-for-drug-manufacturing-and-trial-medicine-production 2024-10-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-to-invest-4-5bn-for-drug-manufacturing-and-trial-medicine-production 2024-10-03T09:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/october-3-2024-jama-commentary-highlights-gap-between-research-results-and 2024-10-03T08:01:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/october-3-2024-jama-commentary-highlights-gap-between-research-results-and 2024-10-03T08:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-randomized-clinical-trial-of-efficacy-and-safety-of-amlodipine-and-candesartan 2024-10-03T07:50:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-randomized-clinical-trial-of-efficacy-and-safety-of-amlodipine-and-candesartan 2024-10-03T07:50:30+00:00 weekly 0.7 https://trial.medpath.com/news/bpd-maintains-qol-vs-pvd-supporting-its-use-as-a-new-soc-in-r-r-myeloma-onclive 2024-10-03T07:42:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bpd-maintains-qol-vs-pvd-supporting-its-use-as-a-new-soc-in-r-r-myeloma-onclive 2024-10-03T07:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/korean-clinical-trials-prove-exosomes-peptides-and-spicules-outperforms-retinol-in-anti-ageing 2024-10-03T07:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/korean-clinical-trials-prove-exosomes-peptides-and-spicules-outperforms-retinol-in-anti-ageing 2024-10-03T07:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-targets-cognitive-recovery-after-brain-injury-rowan-today 2024-10-03T07:33:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-targets-cognitive-recovery-after-brain-injury-rowan-today 2024-10-03T07:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/revvity-s-euroimmun-launches-solution-for-specific-typing-of-alzheimer-s-disease-news-medical 2024-10-03T07:26:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revvity-s-euroimmun-launches-solution-for-specific-typing-of-alzheimer-s-disease-news-medical 2024-10-03T07:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-closes-in-on-cancer-fighting-drug-approval-the-west-australian 2024-10-03T07:13:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharm-closes-in-on-cancer-fighting-drug-approval-the-west-australian 2024-10-03T07:13:32+00:00 weekly 0.7 https://trial.medpath.com/news/mrd-negativity-is-sustained-after-cessation-of-lenalidomide-maintenance-in-multiple-myeloma 2024-10-03T07:09:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrd-negativity-is-sustained-after-cessation-of-lenalidomide-maintenance-in-multiple-myeloma 2024-10-03T07:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/camber-pharmaceuticals-achieves-full-dscsa-compliance-ahead-of-2024-deadline 2024-10-03T07:06:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/camber-pharmaceuticals-achieves-full-dscsa-compliance-ahead-of-2024-deadline 2024-10-03T07:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/recipharm-expands-global-pharmaceutical-development-capabilities-with-strategic-investments 2024-10-03T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recipharm-expands-global-pharmaceutical-development-capabilities-with-strategic-investments 2024-10-03T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gender-gap-in-heart-disease-women-face-higher-misdiagnosis-risks-and-mortality-rates 2024-10-03T06:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gender-gap-in-heart-disease-women-face-higher-misdiagnosis-risks-and-mortality-rates 2024-10-03T06:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/resolution-therapeutics-macrophage-therapy-raises-85-million-labiotech-eu 2024-10-03T06:32:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resolution-therapeutics-macrophage-therapy-raises-85-million-labiotech-eu 2024-10-03T06:32:33+00:00 weekly 0.7 https://trial.medpath.com/news/study-aims-to-resolve-variants-of-uncertain-significance 2024-10-03T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-aims-to-resolve-variants-of-uncertain-significance 2024-10-03T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/high-rates-of-polycythemia-vera-remission-seen-with-ruxolitinib-plus-peg-ifn 2024-10-03T03:27:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-rates-of-polycythemia-vera-remission-seen-with-ruxolitinib-plus-peg-ifn 2024-10-03T03:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/proscia-launches-ai-powered-pathology-platform-to-accelerate-precision-medicine-research 2024-10-03T01:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/proscia-launches-ai-powered-pathology-platform-to-accelerate-precision-medicine-research 2024-10-03T01:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drugs-gene-therapies-clinical-trials-to-watch-right-now-quartz 2024-10-03T00:01:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-drugs-gene-therapies-clinical-trials-to-watch-right-now-quartz 2024-10-03T00:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fully-revokes-authorization-of-gsk-and-vir-s 2024-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-fully-revokes-authorization-of-gsk-and-vir-s 2024-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-t1d-and-integrated-nanotherapeutics-collaborate-to-advance-development 2024-10-02T23:35:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-t1d-and-integrated-nanotherapeutics-collaborate-to-advance-development 2024-10-02T23:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/processa-pharmaceuticals-announces-first-patient-dosed-in-phase-2-clinical-trial-of-ngc 2024-10-02T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/processa-pharmaceuticals-announces-first-patient-dosed-in-phase-2-clinical-trial-of-ngc 2024-10-02T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/noraps-phase-2-trial-to-test-noradrenaline-reuptake-inhibitor-atomoxetine-in-psp 2024-10-02T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noraps-phase-2-trial-to-test-noradrenaline-reuptake-inhibitor-atomoxetine-in-psp 2024-10-02T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/dcisionrt-biosignature-identifies-residual-recurrence-risk-in-her2-3-breast-cancer 2024-10-02T22:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dcisionrt-biosignature-identifies-residual-recurrence-risk-in-her2-3-breast-cancer 2024-10-02T22:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-for-respirx-inhalable-nicotine-replacement-therapy-pharmacy-times 2024-10-02T22:38:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-ind-for-respirx-inhalable-nicotine-replacement-therapy-pharmacy-times 2024-10-02T22:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/three-outcome-designs-for-external-pilot-trials-with-progression-criteria 2024-10-02T22:34:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-outcome-designs-for-external-pilot-trials-with-progression-criteria 2024-10-02T22:34:40+00:00 weekly 0.7 https://trial.medpath.com/news/monogram-technologies-receives-fda-response-for-mbos-tka-system-stock-titan 2024-10-02T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monogram-technologies-receives-fda-response-for-mbos-tka-system-stock-titan 2024-10-02T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/myrtelle-s-canavan-disease-gene-therapy-raav-olig001-aspa-decreases-n 2024-10-02T22:16:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myrtelle-s-canavan-disease-gene-therapy-raav-olig001-aspa-decreases-n 2024-10-02T22:16:51+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-complexities-of-clinical-oncology-bowdoin-college 2024-10-02T22:11:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-the-complexities-of-clinical-oncology-bowdoin-college 2024-10-02T22:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/erleada-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer 2024-10-02T22:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/erleada-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer 2024-10-02T22:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/radiotherapy-vs-transoral-robotic-surgery-for-oropharyngeal-squamous-cell-carcinoma 2024-10-02T21:58:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiotherapy-vs-transoral-robotic-surgery-for-oropharyngeal-squamous-cell-carcinoma 2024-10-02T21:58:13+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-expands-equity-incentive-plan-by-3-million-shares-investing-com-uk 2024-10-02T21:23:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aethlon-medical-expands-equity-incentive-plan-by-3-million-shares-investing-com-uk 2024-10-02T21:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/september-2024-fda-roundup-key-decisions-drive-oncology-forward 2024-10-02T21:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-2024-fda-roundup-key-decisions-drive-oncology-forward 2024-10-02T21:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-examines-standard-vs-extended-lymph-node-removal-for-muscle-invasive 2024-10-02T21:00:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-examines-standard-vs-extended-lymph-node-removal-for-muscle-invasive 2024-10-02T21:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-assessment-of-fecal-microbiota-transplantation-as-an-adjunctive-nature 2024-10-02T20:46:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-efficacy-assessment-of-fecal-microbiota-transplantation-as-an-adjunctive-nature 2024-10-02T20:46:33+00:00 weekly 0.7 https://trial.medpath.com/news/medulloblastoma-initiative-unveils-latest-impact-report-showcasing-breakthrough-fda 2024-10-02T20:34:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medulloblastoma-initiative-unveils-latest-impact-report-showcasing-breakthrough-fda 2024-10-02T20:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/arcus-biosciences-announces-clinical-trial-collaboration-agreement-to-evaluate-yahoo-finance 2024-10-02T20:32:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcus-biosciences-announces-clinical-trial-collaboration-agreement-to-evaluate-yahoo-finance 2024-10-02T20:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-q-a-guidance-on-electronic-records-in-clinical-trials-raps 2024-10-02T20:29:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-finalizes-q-a-guidance-on-electronic-records-in-clinical-trials-raps 2024-10-02T20:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/acurx-reports-positive-trial-results-for-new-antibiotic-02-10-2024-kursiv-kz 2024-10-02T20:18:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurx-reports-positive-trial-results-for-new-antibiotic-02-10-2024-kursiv-kz 2024-10-02T20:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/biotechnology-company-launches-cancer-vaccine-trial-for-dogs-dvm360 2024-10-02T20:12:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotechnology-company-launches-cancer-vaccine-trial-for-dogs-dvm360 2024-10-02T20:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/tryptase-inhibitor-did-not-significantly-affect-time-to-asthma-exacerbation 2024-10-02T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tryptase-inhibitor-did-not-significantly-affect-time-to-asthma-exacerbation 2024-10-02T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/rice-s-biotech-launch-pad-to-lead-commercialization-of-bioelectrical-implant-treatment-for 2024-10-02T19:55:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rice-s-biotech-launch-pad-to-lead-commercialization-of-bioelectrical-implant-treatment-for 2024-10-02T19:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-side-effects-potential-risks-in-cvd-patients-clinical-advisor 2024-10-02T19:12:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-side-effects-potential-risks-in-cvd-patients-clinical-advisor 2024-10-02T19:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/missouri-is-supporting-research-on-how-magic-mushrooms-can-treat-drug-addiction-with 2024-10-02T19:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/missouri-is-supporting-research-on-how-magic-mushrooms-can-treat-drug-addiction-with 2024-10-02T19:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-gets-fda-approval-to-begin-phase-1-trials-of-ai-discovered-cancer-treatment 2024-10-02T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-gets-fda-approval-to-begin-phase-1-trials-of-ai-discovered-cancer-treatment 2024-10-02T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/ninth-circuit-strengthens-fda-authority-to-enforce-drug-regs-against-certain-stem-cell-products 2024-10-02T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ninth-circuit-strengthens-fda-authority-to-enforce-drug-regs-against-certain-stem-cell-products 2024-10-02T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/data-supports-approval-of-biosimilar-aflibercept-for-diabetic-macular-edema 2024-10-02T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-supports-approval-of-biosimilar-aflibercept-for-diabetic-macular-edema 2024-10-02T18:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-drug-that-s-helping-the-world-quit-smoking-except-in-america 2024-10-02T18:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-drug-that-s-helping-the-world-quit-smoking-except-in-america 2024-10-02T18:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-develop-insights-into-kras-mutations-in-pancreatic-cancers-medical-xpress 2024-10-02T17:23:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-develop-insights-into-kras-mutations-in-pancreatic-cancers-medical-xpress 2024-10-02T17:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/anixa-biosciences-seeks-protocol-change-to-enable-repeat-dosing-in-trial-for-ovarian 2024-10-02T17:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anixa-biosciences-seeks-protocol-change-to-enable-repeat-dosing-in-trial-for-ovarian 2024-10-02T17:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/hido-technologies-awarded-phase-ii-sbir-grant-by-national-institute-on-aging-nia-for-prweb 2024-10-02T17:01:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hido-technologies-awarded-phase-ii-sbir-grant-by-national-institute-on-aging-nia-for-prweb 2024-10-02T17:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/biostem-technologies-initiates-br-ac-dfu-101-clinical-trial-globenewswire 2024-10-02T17:01:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biostem-technologies-initiates-br-ac-dfu-101-clinical-trial-globenewswire 2024-10-02T17:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/emergex-t-cell-priming-vaccine-candidate-for-betacoronaviruses-selected-by-nih-niaid 2024-10-02T16:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emergex-t-cell-priming-vaccine-candidate-for-betacoronaviruses-selected-by-nih-niaid 2024-10-02T16:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/anti-cancer-antibodies-may-aid-early-melanoma-detection-inside-precision-medicine 2024-10-02T16:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-cancer-antibodies-may-aid-early-melanoma-detection-inside-precision-medicine 2024-10-02T16:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/apalutamide-associated-with-improved-survival-vs-enzalutamide-in-mcspc-urology-times 2024-10-02T16:43:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apalutamide-associated-with-improved-survival-vs-enzalutamide-in-mcspc-urology-times 2024-10-02T16:43:42+00:00 weekly 0.7 https://trial.medpath.com/news/decadine-demonstrates-therapeutic-potential-for-the-treatment-of-myelofibrosis 2024-10-02T16:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/decadine-demonstrates-therapeutic-potential-for-the-treatment-of-myelofibrosis 2024-10-02T16:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/conformal-medical-kicks-off-left-atrial-appendage-occlusion-device-trial-massdevice 2024-10-02T16:16:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conformal-medical-kicks-off-left-atrial-appendage-occlusion-device-trial-massdevice 2024-10-02T16:16:30+00:00 weekly 0.7 https://trial.medpath.com/news/biointellisense-wins-fda-nod-for-biobutton-multi-patient-wearable-monitor-massdevice 2024-10-02T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biointellisense-wins-fda-nod-for-biobutton-multi-patient-wearable-monitor-massdevice 2024-10-02T16:16:29+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-and-functional-landscape-of-malignant-serous-effusions-for-precision-oncology 2024-10-02T15:38:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecular-and-functional-landscape-of-malignant-serous-effusions-for-precision-oncology 2024-10-02T15:38:01+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings-forbes 2024-10-02T15:29:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings-forbes 2024-10-02T15:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/masld-a-disease-in-flux-nature-reviews-gastroenterology-hepatology 2024-10-02T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/masld-a-disease-in-flux-nature-reviews-gastroenterology-hepatology 2024-10-02T14:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/exscientia-outline-robot-and-ai-use-in-drug-discovery-workflow-pharmaceutical-technology 2024-10-02T14:44:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exscientia-outline-robot-and-ai-use-in-drug-discovery-workflow-pharmaceutical-technology 2024-10-02T14:44:16+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-ties-up-with-gilead-to-manufacture-commercialise-hiv-drug-business-standard 2024-10-02T14:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-ties-up-with-gilead-to-manufacture-commercialise-hiv-drug-business-standard 2024-10-02T14:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-authorizes-launch-of-clinical-trial-to-support-new-treatment-development-for-progeria 2024-10-02T14:34:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-authorizes-launch-of-clinical-trial-to-support-new-treatment-development-for-progeria 2024-10-02T14:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/ions-rare-neurology-disorder-candidate-gets-fda-s-fast-track-tag-barchart-com 2024-10-02T14:23:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ions-rare-neurology-disorder-candidate-gets-fda-s-fast-track-tag-barchart-com 2024-10-02T14:23:44+00:00 weekly 0.7 https://trial.medpath.com/news/safer-epilepsy-treatment-for-pregnant-women-with-drug-combo-neuroscience-news 2024-10-02T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safer-epilepsy-treatment-for-pregnant-women-with-drug-combo-neuroscience-news 2024-10-02T14:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/onyda-xr-first-liquid-nonstimulant-for-adhd-now-available-in-us-drug-topics 2024-10-02T14:13:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onyda-xr-first-liquid-nonstimulant-for-adhd-now-available-in-us-drug-topics 2024-10-02T14:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/lymphoplasmacytic-lymphoma-vaccine-leads-to-potential-clinical-benefit-as-early-intervention 2024-10-02T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lymphoplasmacytic-lymphoma-vaccine-leads-to-potential-clinical-benefit-as-early-intervention 2024-10-02T14:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/with-115m-more-triveni-accelerates-immune-drug-work-biopharma-dive 2024-10-02T14:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-115m-more-triveni-accelerates-immune-drug-work-biopharma-dive 2024-10-02T14:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/alterity-therapeutics-raises-profile-with-multiple-data-presentations-at-the-international-biospace 2024-10-02T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alterity-therapeutics-raises-profile-with-multiple-data-presentations-at-the-international-biospace 2024-10-02T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/adoptive-cell-therapy-clinical-trials-report-2024-trends 2024-10-02T13:31:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adoptive-cell-therapy-clinical-trials-report-2024-trends 2024-10-02T13:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/hepatology-month-in-review-september-2024-hcplive 2024-10-02T13:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hepatology-month-in-review-september-2024-hcplive 2024-10-02T13:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/jaguar-s-diarrhoea-drug-shows-benefit-in-phase-iii-breast-cancer-subgroup 2024-10-02T13:28:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jaguar-s-diarrhoea-drug-shows-benefit-in-phase-iii-breast-cancer-subgroup 2024-10-02T13:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/alzecure-s-acd856-s-effects-to-be-presented-at-alzheimer-s-conference-pharmatimes 2024-10-02T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzecure-s-acd856-s-effects-to-be-presented-at-alzheimer-s-conference-pharmatimes 2024-10-02T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/oryzon-genomics-fda-aligns-on-phase-iii-bpd-plans-edison-investment-research 2024-10-02T12:56:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oryzon-genomics-fda-aligns-on-phase-iii-bpd-plans-edison-investment-research 2024-10-02T12:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluating 2024-10-02T12:50:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-announces-presentation-of-promising-phase-i-data-evaluating 2024-10-02T12:50:54+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-announces-positive-data-for-sotyktu-in-moderate-to-severe-psoriasis 2024-10-02T12:43:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-announces-positive-data-for-sotyktu-in-moderate-to-severe-psoriasis 2024-10-02T12:43:39+00:00 weekly 0.7 https://trial.medpath.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye 2024-10-02T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye 2024-10-02T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/volastra-therapeutics-granted-fda-fast-track-designation-for-novel-kif18a-inhibitor-in 2024-10-02T12:36:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/volastra-therapeutics-granted-fda-fast-track-designation-for-novel-kif18a-inhibitor-in 2024-10-02T12:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-abionic-s-ivd-capsule-psp-for-the-early-detection-of-sepsis-biospace 2024-10-02T12:36:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-abionic-s-ivd-capsule-psp-for-the-early-detection-of-sepsis-biospace 2024-10-02T12:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-36-month-overall-survival-rate-of-globenewswire 2024-10-02T12:22:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-36-month-overall-survival-rate-of-globenewswire 2024-10-02T12:22:10+00:00 weekly 0.7 https://trial.medpath.com/news/a-digital-intervention-for-cognitive-deficits-following-covid-19-a-randomized-clinical-trial 2024-10-02T12:15:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-digital-intervention-for-cognitive-deficits-following-covid-19-a-randomized-clinical-trial 2024-10-02T12:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-3-clinical-trial-of-ugn-103-a-next-generation-mitomycin 2024-10-02T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-3-clinical-trial-of-ugn-103-a-next-generation-mitomycin 2024-10-02T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/setpoint-medical-receives-fda-s-ide-approval-for-u-s-pilot-study-of-neuroimmune 2024-10-02T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/setpoint-medical-receives-fda-s-ide-approval-for-u-s-pilot-study-of-neuroimmune 2024-10-02T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/genieus-genomics-announces-completion-of-phase-2-clinical-trial-enrollment-ein-news 2024-10-02T12:02:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genieus-genomics-announces-completion-of-phase-2-clinical-trial-enrollment-ein-news 2024-10-02T12:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/the-influence-of-simultaneous-posterior-colporrhaphy-and-perineoplasty-on-the-efficiency 2024-10-02T11:34:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-influence-of-simultaneous-posterior-colporrhaphy-and-perineoplasty-on-the-efficiency 2024-10-02T11:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/toleranzia-submits-a-clinical-trial-application-cta-for-the-drug-candidate-tol2-for-the-placera 2024-10-02T11:13:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toleranzia-submits-a-clinical-trial-application-cta-for-the-drug-candidate-tol2-for-the-placera 2024-10-02T11:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-to-present-at-the-2024-cell-gene-meeting-on-the-mesa-globenewswire 2024-10-02T10:50:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-to-present-at-the-2024-cell-gene-meeting-on-the-mesa-globenewswire 2024-10-02T10:50:15+00:00 weekly 0.7 https://trial.medpath.com/news/amsel-medical-signs-7-45m-phase-iii-sbir-contract-yahoo-finance 2024-10-02T10:49:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amsel-medical-signs-7-45m-phase-iii-sbir-contract-yahoo-finance 2024-10-02T10:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/genenta-secures-approval-for-innovative-trial-for-metastatic-renal-cell-cancer-stock-titan 2024-10-02T10:48:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genenta-secures-approval-for-innovative-trial-for-metastatic-renal-cell-cancer-stock-titan 2024-10-02T10:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/one-in-three-americans-has-a-dysfunctional-metabolism-clinical-trial-suggests-intermittent 2024-10-02T10:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/one-in-three-americans-has-a-dysfunctional-metabolism-clinical-trial-suggests-intermittent 2024-10-02T10:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/surmodics-receives-fda-510-k-clearance-for-pounce-xl-thrombectomy-system 2024-10-02T09:43:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surmodics-receives-fda-510-k-clearance-for-pounce-xl-thrombectomy-system 2024-10-02T09:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/fierce-names-insilico-medicine-as-one-of-its-fierce-50-honorees-of-2024-eurekalert 2024-10-02T09:25:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fierce-names-insilico-medicine-as-one-of-its-fierce-50-honorees-of-2024-eurekalert 2024-10-02T09:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/her2-directed-adcs-spread-like-wildfire-across-the-spectrum-of-solid-malignancies 2024-10-02T09:16:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/her2-directed-adcs-spread-like-wildfire-across-the-spectrum-of-solid-malignancies 2024-10-02T09:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/can-flashing-lights-stall-alzheimer-s-what-the-science-shows-nature 2024-10-02T09:16:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-flashing-lights-stall-alzheimer-s-what-the-science-shows-nature 2024-10-02T09:16:15+00:00 weekly 0.7 https://trial.medpath.com/news/brain-zap-treatment-could-get-arms-hands-moving-after-head-injury 2024-10-02T09:10:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-zap-treatment-could-get-arms-hands-moving-after-head-injury 2024-10-02T09:10:52+00:00 weekly 0.7 https://trial.medpath.com/news/coffee-water-soda-which-raise-your-odds-for-stroke 2024-10-02T09:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/coffee-water-soda-which-raise-your-odds-for-stroke 2024-10-02T09:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/a-phenocopy-signature-of-tp53-loss-predicts-response-to-chemotherapy 2024-10-02T08:47:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phenocopy-signature-of-tp53-loss-predicts-response-to-chemotherapy 2024-10-02T08:47:29+00:00 weekly 0.7 https://trial.medpath.com/news/spineguard-obtains-fda-clearance-for-commercial-release-of-its-psifguard-new-smart 2024-10-02T08:46:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spineguard-obtains-fda-clearance-for-commercial-release-of-its-psifguard-new-smart 2024-10-02T08:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/jlk-s-ai-stroke-solution-receives-fda-approval-businesskorea 2024-10-02T08:43:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jlk-s-ai-stroke-solution-receives-fda-approval-businesskorea 2024-10-02T08:43:41+00:00 weekly 0.7 https://trial.medpath.com/news/after-cassava-alzheimer-drug-fiasco-fda-must-protect-patients-stat-news 2024-10-02T08:39:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-cassava-alzheimer-drug-fiasco-fda-must-protect-patients-stat-news 2024-10-02T08:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-updates-shareholders-on-clinical-progress-and-financial-status 2024-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ensysce-biosciences-updates-shareholders-on-clinical-progress-and-financial-status 2024-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/terrapower-isotopes-brings-actinium-225-to-market 2024-10-02T07:57:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/terrapower-isotopes-brings-actinium-225-to-market 2024-10-02T07:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/pbm-reform-urgently-needed-as-drug-pricing-crisis-deepens-industry-analysis-shows 2024-10-02T07:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbm-reform-urgently-needed-as-drug-pricing-crisis-deepens-industry-analysis-shows 2024-10-02T07:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/allogeneic-t-cell-therapy-produces-efficacy-at-10-months-in-stage-iv-metastatic-nsclc 2024-10-02T07:12:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allogeneic-t-cell-therapy-produces-efficacy-at-10-months-in-stage-iv-metastatic-nsclc 2024-10-02T07:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/exact-therapeutics-to-present-at-the-bi-annual-contrast-media-research-cmr-symposium-2024 2024-10-02T06:42:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-therapeutics-to-present-at-the-bi-annual-contrast-media-research-cmr-symposium-2024 2024-10-02T06:42:25+00:00 weekly 0.7 https://trial.medpath.com/news/wuxi-apptec-predicts-shift-from-antibodies-to-peptides-in-radiopharmaceutical-development 2024-10-02T06:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wuxi-apptec-predicts-shift-from-antibodies-to-peptides-in-radiopharmaceutical-development 2024-10-02T06:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/halda-therapeutics-appoints-christian-schade-as-ceo-citybiz 2024-10-02T06:05:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halda-therapeutics-appoints-christian-schade-as-ceo-citybiz 2024-10-02T06:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/scope-of-things-trial-planning-skews-conclusions-ai-diversity-help-news-of-the-month 2024-10-02T05:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scope-of-things-trial-planning-skews-conclusions-ai-diversity-help-news-of-the-month 2024-10-02T05:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors 2024-10-02T04:18:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-basket-trial-of-dual-anti-ctla-4-and-anti-pd-1-blockade-in-rare-tumors 2024-10-02T04:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-inc-latest-stock-news-market-updates 2024-10-02T02:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-inc-latest-stock-news-market-updates 2024-10-02T02:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/merck-completes-acquisition-of-investigational-bispecific-antibody-therapy-from-curon 2024-10-02T02:28:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-completes-acquisition-of-investigational-bispecific-antibody-therapy-from-curon 2024-10-02T02:28:44+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-community-based-trials-drive-145-increase-in-clinical-trial-engagement-promising-greater-diversity 2024-10-02T01:17:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-community-based-trials-drive-145-increase-in-clinical-trial-engagement-promising-greater-diversity 2024-10-02T01:17:46+00:00 weekly 0.7 https://trial.medpath.com/news/avmf-stanton-foundation-offering-150000-research-grant 2024-10-02T01:06:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avmf-stanton-foundation-offering-150000-research-grant 2024-10-02T01:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/thryv-therapeutics-granted-fda-orphan-drug-designation-for-lqt-1213-in-long-qt 2024-10-02T01:01:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thryv-therapeutics-granted-fda-orphan-drug-designation-for-lqt-1213-in-long-qt 2024-10-02T01:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/tnk-stroke-treatment-how-it-works-administration-and-more-medicalnewstoday 2024-10-02T00:44:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tnk-stroke-treatment-how-it-works-administration-and-more-medicalnewstoday 2024-10-02T00:44:10+00:00 weekly 0.7 https://trial.medpath.com/news/nearly-half-of-fda-authorized-ai-tools-may-provide-little-benefit-medical-economics 2024-10-02T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nearly-half-of-fda-authorized-ai-tools-may-provide-little-benefit-medical-economics 2024-10-02T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-class-ar-degrader-shows-promise-in-castration-resistant-prostate-cancer-dana-rathkopf 2024-10-02T00:22:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-class-ar-degrader-shows-promise-in-castration-resistant-prostate-cancer-dana-rathkopf 2024-10-02T00:22:12+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-radiation-oncologist-highlights-new-insights-on-single-fraction-radiation-for 2024-10-01T23:19:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roswell-park-radiation-oncologist-highlights-new-insights-on-single-fraction-radiation-for 2024-10-01T23:19:39+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-submits-fda-application-for-expanded-use-of-skytrofa-medwatch 2024-10-01T22:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-submits-fda-application-for-expanded-use-of-skytrofa-medwatch 2024-10-01T22:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-combination-of-nivolumab-immunotherapy-with-radiation-therapy-and-urotoday 2024-10-01T22:27:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-combination-of-nivolumab-immunotherapy-with-radiation-therapy-and-urotoday 2024-10-01T22:27:41+00:00 weekly 0.7 https://trial.medpath.com/news/suicide-attempts-reduced-by-25-with-integrated-primary-care-intervention 2024-10-01T22:25:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suicide-attempts-reduced-by-25-with-integrated-primary-care-intervention 2024-10-01T22:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential 2024-10-01T22:17:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maze-therapeutics-initiates-phase-1-first-in-human-trial-evaluating-mze782-as-a-potential 2024-10-01T22:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/bms-986393-shows-first-in-class-potential-in-relapsed-refractory-multiple-myeloma 2024-10-01T21:31:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-986393-shows-first-in-class-potential-in-relapsed-refractory-multiple-myeloma 2024-10-01T21:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/perimeter-announces-completion-of-patient-enrollment-in-pivotal-clinical-trial-evaluating 2024-10-01T20:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perimeter-announces-completion-of-patient-enrollment-in-pivotal-clinical-trial-evaluating 2024-10-01T20:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/breast-cancer-patients-denied-precious-time-with-loved-ones-as-new-drug-korserdu-rejected-on-nhs 2024-10-01T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-cancer-patients-denied-precious-time-with-loved-ones-as-new-drug-korserdu-rejected-on-nhs 2024-10-01T20:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-radiotherapy-modality-appears-safe-feasible-in-high-grade-glioma 2024-10-01T19:33:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-radiotherapy-modality-appears-safe-feasible-in-high-grade-glioma 2024-10-01T19:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/outrage-of-the-month-expanded-fda-approval-of-a-gene-therapy-for-muscular-dystrophy 2024-10-01T19:31:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outrage-of-the-month-expanded-fda-approval-of-a-gene-therapy-for-muscular-dystrophy 2024-10-01T19:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/eirion-therapeutics-announces-results-of-first-in-human-clinical-trial-evaluating-ready-to 2024-10-01T19:02:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eirion-therapeutics-announces-results-of-first-in-human-clinical-trial-evaluating-ready-to 2024-10-01T19:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-sepiapterin-for-pr-newswire 2024-10-01T19:01:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for-sepiapterin-for-pr-newswire 2024-10-01T19:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-s-potentially-revolutionary-ability-to-treat-depression-hinges-on-fda-approval 2024-10-01T18:49:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-s-potentially-revolutionary-ability-to-treat-depression-hinges-on-fda-approval 2024-10-01T18:49:03+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-announces-u-s-fda-has-updated-the-pemgardatm-eua-fact-sheet-with-accurate 2024-10-01T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-announces-u-s-fda-has-updated-the-pemgardatm-eua-fact-sheet-with-accurate 2024-10-01T18:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-patients-who-experience-cognitive-decline-after-radiation-treatment-for-brain 2024-10-01T17:44:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-patients-who-experience-cognitive-decline-after-radiation-treatment-for-brain 2024-10-01T17:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/ultrasound-method-linked-with-improved-survival-in-patients-with-crc-liver-metastases 2024-10-01T17:43:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultrasound-method-linked-with-improved-survival-in-patients-with-crc-liver-metastases 2024-10-01T17:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/pre-operative-prediction-of-bcr-free-survival-with-mrna-variables-in-prostate-cancer-plos-one 2024-10-01T17:40:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pre-operative-prediction-of-bcr-free-survival-with-mrna-variables-in-prostate-cancer-plos-one 2024-10-01T17:40:45+00:00 weekly 0.7 https://trial.medpath.com/news/can-telehealth-help-patients-stick-with-buprenorphinie-for-opioid-addiction-uc-davis-health 2024-10-01T17:39:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-telehealth-help-patients-stick-with-buprenorphinie-for-opioid-addiction-uc-davis-health 2024-10-01T17:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/gritstone-bio-reports-positive-interim-phase-2-data-investing-com 2024-10-01T17:26:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gritstone-bio-reports-positive-interim-phase-2-data-investing-com 2024-10-01T17:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/for-the-first-time-a-drug-developed-at-uwm-enters-fda-clinical-trials-letters-science 2024-10-01T17:15:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/for-the-first-time-a-drug-developed-at-uwm-enters-fda-clinical-trials-letters-science 2024-10-01T17:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/5-fda-decisions-to-watch-in-the-fourth-quarter-biopharma-dive 2024-10-01T17:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-fda-decisions-to-watch-in-the-fourth-quarter-biopharma-dive 2024-10-01T17:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/ember-imlunestrant-in-estrogen-receptor-positive-her2-negative-advanced-breast-cancer 2024-10-01T16:30:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ember-imlunestrant-in-estrogen-receptor-positive-her2-negative-advanced-breast-cancer 2024-10-01T16:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/acumen-and-lonza-expand-collaboration-for-early-alzheimer-s-drug 2024-10-01T16:17:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acumen-and-lonza-expand-collaboration-for-early-alzheimer-s-drug 2024-10-01T16:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/kailera-therapeutics-emerges-from-stealth-with-400m-for-obesity-drugs-biopharma-dive 2024-10-01T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kailera-therapeutics-emerges-from-stealth-with-400m-for-obesity-drugs-biopharma-dive 2024-10-01T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-phase-1-data-highlighting-camonsertib-in-combination 2024-10-01T16:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-announces-phase-1-data-highlighting-camonsertib-in-combination 2024-10-01T16:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-lecanemab-ema-re-examining-marketing-authorisation-euractiv 2024-10-01T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-lecanemab-ema-re-examining-marketing-authorisation-euractiv 2024-10-01T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-weight-loss-meds-could-interfere-with-endoscopy-colonoscopy 2024-10-01T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-weight-loss-meds-could-interfere-with-endoscopy-colonoscopy 2024-10-01T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-identify-new-therapeutic-approach-to-preventing-cancer-from-spreading-to-the-brain 2024-10-01T15:05:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-identify-new-therapeutic-approach-to-preventing-cancer-from-spreading-to-the-brain 2024-10-01T15:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/is-gene-therapy-the-next-big-step-in-vision-loss-treatment-medicalnewstoday 2024-10-01T15:03:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-gene-therapy-the-next-big-step-in-vision-loss-treatment-medicalnewstoday 2024-10-01T15:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-receives-positive-chmp-opinion-from-european-medicines-agency-for-its-bizz-buzz 2024-10-01T14:50:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-receives-positive-chmp-opinion-from-european-medicines-agency-for-its-bizz-buzz 2024-10-01T14:50:14+00:00 weekly 0.7 https://trial.medpath.com/news/ron-renaud-s-new-obesity-biotech-kailera-has-400m-to-go-straight-to-phase-3 2024-10-01T14:43:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ron-renaud-s-new-obesity-biotech-kailera-has-400m-to-go-straight-to-phase-3 2024-10-01T14:43:43+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-at-children-s-of-alabama-help-find-the-best-treatments-for-children-with-cancer 2024-10-01T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-at-children-s-of-alabama-help-find-the-best-treatments-for-children-with-cancer 2024-10-01T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/drones-and-biotechs-are-moving-this-morning-raging-bull 2024-10-01T14:39:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drones-and-biotechs-are-moving-this-morning-raging-bull 2024-10-01T14:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-declared-international-public-health-emergency-as-cases-continue-to-rise 2024-10-01T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpox-declared-international-public-health-emergency-as-cases-continue-to-rise 2024-10-01T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-treatment-provides-orr-and-pfs-benefit-in-pretreated-metastatic-solid-tumors 2024-10-01T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-treatment-provides-orr-and-pfs-benefit-in-pretreated-metastatic-solid-tumors 2024-10-01T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/rationale-and-design-of-the-study-to-investigate-the-metabolic-action-of-imeglimin-on 2024-10-01T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rationale-and-design-of-the-study-to-investigate-the-metabolic-action-of-imeglimin-on 2024-10-01T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/teva-pharma-launches-octreotide-acetate-for-injectable-suspension-quick-facts 2024-10-01T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-pharma-launches-octreotide-acetate-for-injectable-suspension-quick-facts 2024-10-01T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/ascelia-pharma-s-primary-results-from-phase-iii-study-to-be-presented-at-rsna-conference 2024-10-01T14:01:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascelia-pharma-s-primary-results-from-phase-iii-study-to-be-presented-at-rsna-conference 2024-10-01T14:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/denifanstat-receives-breakthrough-therapy-designation-for-noncirrhotic-mash-hcplive 2024-10-01T13:56:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denifanstat-receives-breakthrough-therapy-designation-for-noncirrhotic-mash-hcplive 2024-10-01T13:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-pharmaceuticals-lasofoxifene-demonstrates-anti-estrogen-therapy-increases 2024-10-01T13:32:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sermonix-pharmaceuticals-lasofoxifene-demonstrates-anti-estrogen-therapy-increases 2024-10-01T13:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-aims-to-expand-weight-loss-drug-trials-to-those-at-risk-not-just-overweight 2024-10-01T13:13:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-aims-to-expand-weight-loss-drug-trials-to-those-at-risk-not-just-overweight 2024-10-01T13:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/mechanism-behind-ulixacaltamide-to-treat-essential-tremor-marcio-souza-neurologylive 2024-10-01T12:49:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mechanism-behind-ulixacaltamide-to-treat-essential-tremor-marcio-souza-neurologylive 2024-10-01T12:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/barinthus-bio-completes-enrollment-for-phase-2b-hbv003-globenewswire 2024-10-01T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barinthus-bio-completes-enrollment-for-phase-2b-hbv003-globenewswire 2024-10-01T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-announces-upcoming-oral-presentation-at-the-society-globenewswire 2024-10-01T12:03:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioatla-announces-upcoming-oral-presentation-at-the-society-globenewswire 2024-10-01T12:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/igm-biosciences-shifts-focus-to-autoimmune-disease-research-amid-staff-layoffs 2024-10-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/igm-biosciences-shifts-focus-to-autoimmune-disease-research-amid-staff-layoffs 2024-10-01T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-therapeutics-to-present-at-october-2024-investor-conferences-biospace 2024-10-01T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemomab-therapeutics-to-present-at-october-2024-investor-conferences-biospace 2024-10-01T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/register-certain-tests-for-phase-3-of-the-dex-z-codes-uhcprovider-com 2024-10-01T11:55:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/register-certain-tests-for-phase-3-of-the-dex-z-codes-uhcprovider-com 2024-10-01T11:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-expands-clinical-team-to-support-cyb003-phase-3-program-morningstar 2024-10-01T11:41:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-expands-clinical-team-to-support-cyb003-phase-3-program-morningstar 2024-10-01T11:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-pharma-receives-us-fda-approval-for-an-antibiotics-tablet-ndtv-profit 2024-10-01T11:23:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurobindo-pharma-receives-us-fda-approval-for-an-antibiotics-tablet-ndtv-profit 2024-10-01T11:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-enrolls-last-patient-for-planned-unblinded-interim-analysis-in-shield-ii-tipranks 2024-10-01T11:22:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polypid-enrolls-last-patient-for-planned-unblinded-interim-analysis-in-shield-ii-tipranks 2024-10-01T11:22:52+00:00 weekly 0.7 https://trial.medpath.com/news/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T11:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T11:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/edap-announces-first-patients-treated-in-phase-i-ii-study-evaluating-focal-one-robotic 2024-10-01T11:12:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edap-announces-first-patients-treated-in-phase-i-ii-study-evaluating-focal-one-robotic 2024-10-01T11:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/cytosorbents-submits-drugsorb-atr-marketing-application-to-globenewswire 2024-10-01T11:05:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytosorbents-submits-drugsorb-atr-marketing-application-to-globenewswire 2024-10-01T11:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/shattuck-labs-provides-company-update-and-announces-sl-325-globenewswire 2024-10-01T10:33:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shattuck-labs-provides-company-update-and-announces-sl-325-globenewswire 2024-10-01T10:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/spima-therapeutics-starts-with-global-licence-agreement-european-biotechnology 2024-10-01T10:26:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spima-therapeutics-starts-with-global-licence-agreement-european-biotechnology 2024-10-01T10:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-selects-ergomed-as-cro-as-it-gears-up-for-confirmatory-fda-registration-study 2024-10-01T10:25:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cel-sci-selects-ergomed-as-cro-as-it-gears-up-for-confirmatory-fda-registration-study 2024-10-01T10:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/a-review-of-recent-clinical-trials-to-evaluate-disease-modifying-therapies-in-the-treatment-frontiers 2024-10-01T09:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-review-of-recent-clinical-trials-to-evaluate-disease-modifying-therapies-in-the-treatment-frontiers 2024-10-01T09:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/spago-nanomedical-in-new-phase-with-full-focus-on-the-tumorad-program 2024-10-01T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spago-nanomedical-in-new-phase-with-full-focus-on-the-tumorad-program 2024-10-01T09:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-govitecan-in-hr-her2-metastatic-breast-cancer-the-randomized-phase-3 2024-10-01T09:50:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-govitecan-in-hr-her2-metastatic-breast-cancer-the-randomized-phase-3 2024-10-01T09:50:19+00:00 weekly 0.7 https://trial.medpath.com/news/kezar-life-sciences-suspends-subject-enrolment-in-trial-of-lupus-nephritis-drug 2024-10-01T09:46:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kezar-life-sciences-suspends-subject-enrolment-in-trial-of-lupus-nephritis-drug 2024-10-01T09:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/black-white-cancer-patients-now-benefit-equally-from-cord-blood-therapy 2024-10-01T09:10:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/black-white-cancer-patients-now-benefit-equally-from-cord-blood-therapy 2024-10-01T09:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/covid-shot-lowers-your-odds-for-covid-linked-heart-trouble 2024-10-01T09:10:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-shot-lowers-your-odds-for-covid-linked-heart-trouble 2024-10-01T09:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/arun-upadhyay-phd-on-results-from-ird-gene-therapy-ocu400-s-phase-1-2-trial 2024-10-01T08:47:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arun-upadhyay-phd-on-results-from-ird-gene-therapy-ocu400-s-phase-1-2-trial 2024-10-01T08:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-conversion-practices-to-increased-mental-health-risks-in-lgbtq-adults 2024-10-01T08:13:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-conversion-practices-to-increased-mental-health-risks-in-lgbtq-adults 2024-10-01T08:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/incannex-healthcare-inc-reports-fiscal-full-year-2024-financial-results-and-business-updates 2024-10-01T08:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incannex-healthcare-inc-reports-fiscal-full-year-2024-financial-results-and-business-updates 2024-10-01T08:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-h1-2024-results-and-provides-business-update-biospace 2024-10-01T07:58:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-h1-2024-results-and-provides-business-update-biospace 2024-10-01T07:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/cartherics-raises-over-15-million-in-oversubscribed-private-financing-round-to-advance 2024-10-01T07:58:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cartherics-raises-over-15-million-in-oversubscribed-private-financing-round-to-advance 2024-10-01T07:58:44+00:00 weekly 0.7 https://trial.medpath.com/news/drug-shortages-in-australia-highlight-critical-need-to-include-pregnant-women-in-clinical-trials 2024-10-01T06:26:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-shortages-in-australia-highlight-critical-need-to-include-pregnant-women-in-clinical-trials 2024-10-01T06:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-low-intent-for-respiratory-vaccinations-among-us-adults-for-2024-2025-season 2024-10-01T05:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-reveals-low-intent-for-respiratory-vaccinations-among-us-adults-for-2024-2025-season 2024-10-01T05:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-promising-new-treatment-option-for-patients-with-treatment-resistant 2024-10-01T05:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-highlights-promising-new-treatment-option-for-patients-with-treatment-resistant 2024-10-01T05:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/key-medical-conferences-set-to-shape-biopharma-industry-in-2025 2024-10-01T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-medical-conferences-set-to-shape-biopharma-industry-in-2025 2024-10-01T04:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/talapro-2-analysis-talazoparib-enzalutamide-combo-in-pretreated-mcrpc-neeraj-agarwal 2024-10-01T04:25:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/talapro-2-analysis-talazoparib-enzalutamide-combo-in-pretreated-mcrpc-neeraj-agarwal 2024-10-01T04:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/avera-medical-minute-avera-offers-phase-1-clinical-trials-for-cancer-patients-dakota-news-now 2024-10-01T03:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avera-medical-minute-avera-offers-phase-1-clinical-trials-for-cancer-patients-dakota-news-now 2024-10-01T03:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/msd-terminates-phase-ii-trials-for-alzheimer-s-drug-due-to-liver-toxicity-msn 2024-10-01T02:53:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-terminates-phase-ii-trials-for-alzheimer-s-drug-due-to-liver-toxicity-msn 2024-10-01T02:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T02:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zilganersen-granted-u-s-fda-fast-track-designation-for-people-living-with-alexander-disease 2024-10-01T02:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/llms-set-to-transform-clinical-trial-management-through-enhanced-irt-systems 2024-10-01T00:49:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/llms-set-to-transform-clinical-trial-management-through-enhanced-irt-systems 2024-10-01T00:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-enrolls-first-patient-in-phase-2-study-of-st316 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sapience-therapeutics-enrolls-first-patient-in-phase-2-study-of-st316 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-prophylaxis-for-the-prevention-of-sexually 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doxycycline-prophylaxis-for-the-prevention-of-sexually 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-i-study-of-iag933-in-patients-with-advanced 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-i-study-of-iag933-in-patients-with-advanced 2024-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sonrotoclax-dexamethasone-combo-is-tolerable-generates-deep-responses-in-t-11-14-r 2024-09-30T23:48:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonrotoclax-dexamethasone-combo-is-tolerable-generates-deep-responses-in-t-11-14-r 2024-09-30T23:48:59+00:00 weekly 0.7 https://trial.medpath.com/news/clinuvel-files-canadian-new-drug-submission-for-scenesse-r-in-epp-globenewswire 2024-09-30T23:11:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinuvel-files-canadian-new-drug-submission-for-scenesse-r-in-epp-globenewswire 2024-09-30T23:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/hypofractionated-rt-after-mastectomy-is-noninferior-to-soc-in-breast-cancer 2024-09-30T23:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hypofractionated-rt-after-mastectomy-is-noninferior-to-soc-in-breast-cancer 2024-09-30T23:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/redhill-announces-new-u-s-coronavirus-patent-for-opaganib-valid-through-2041 2024-09-30T23:01:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/redhill-announces-new-u-s-coronavirus-patent-for-opaganib-valid-through-2041 2024-09-30T23:01:08+00:00 weekly 0.7 https://trial.medpath.com/news/buy-recommendation-for-bridgebio-pharma-amidst-promising-drug-trials-and-upcoming 2024-09-30T22:31:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-recommendation-for-bridgebio-pharma-amidst-promising-drug-trials-and-upcoming 2024-09-30T22:31:35+00:00 weekly 0.7 https://trial.medpath.com/news/legend-biotech-reiterates-stock-target-overweight-on-phase-iii-data-investing-com 2024-09-30T22:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/legend-biotech-reiterates-stock-target-overweight-on-phase-iii-data-investing-com 2024-09-30T22:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/struggling-to-find-an-effective-depression-treatment-the-reporter-uab 2024-09-30T22:10:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/struggling-to-find-an-effective-depression-treatment-the-reporter-uab 2024-09-30T22:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/roche-turns-to-a-startup-in-search-for-new-breast-cancer-drugs-biopharma-dive 2024-09-30T22:06:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-turns-to-a-startup-in-search-for-new-breast-cancer-drugs-biopharma-dive 2024-09-30T22:06:11+00:00 weekly 0.7 https://trial.medpath.com/news/america-s-nobel-goes-to-a-power-couple-who-made-a-startling-discovery-about-hiv 2024-09-30T22:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/america-s-nobel-goes-to-a-power-couple-who-made-a-startling-discovery-about-hiv 2024-09-30T22:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/university-awarded-12-million-to-further-develop-opioid-use-disorder-drug 2024-09-30T21:51:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-awarded-12-million-to-further-develop-opioid-use-disorder-drug 2024-09-30T21:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-biosciences-s-crinecerfont-is-set-to-transform-the-congenital-adrenal-pr-newswire 2024-09-30T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurocrine-biosciences-s-crinecerfont-is-set-to-transform-the-congenital-adrenal-pr-newswire 2024-09-30T21:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-radiation-oncologist-honored-for-prostate-cancer-care-and-research-newswise 2024-09-30T21:18:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsf-radiation-oncologist-honored-for-prostate-cancer-care-and-research-newswise 2024-09-30T21:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/trial-supports-radiotherapy-and-cisplatin-remaining-as-the-standard-of-care-for-p16 2024-09-30T21:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-supports-radiotherapy-and-cisplatin-remaining-as-the-standard-of-care-for-p16 2024-09-30T21:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/triplet-vs-soc-explored-in-metastatic-prostate-cancer-targeted-oncology 2024-09-30T21:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triplet-vs-soc-explored-in-metastatic-prostate-cancer-targeted-oncology 2024-09-30T21:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/women-in-medicine-month-celebrating-women-advancing-radiology 2024-09-30T21:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/women-in-medicine-month-celebrating-women-advancing-radiology 2024-09-30T21:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/study-time-restricted-eating-may-improve-health-of-adults-with-metabolic-syndrome 2024-09-30T21:00:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-time-restricted-eating-may-improve-health-of-adults-with-metabolic-syndrome 2024-09-30T21:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/novel-pet-imaging-agent-earns-fast-track-status-for-psma-prostate-cancer 2024-09-30T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-pet-imaging-agent-earns-fast-track-status-for-psma-prostate-cancer 2024-09-30T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-first-patient-dosed-in-liger-hn1-a-phase-3-trial-evaluating 2024-09-30T20:16:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-announces-first-patient-dosed-in-liger-hn1-a-phase-3-trial-evaluating 2024-09-30T20:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/standard-chemoradiation-outperforms-de-intensified-treatments-in-hpv-associated-news-medical 2024-09-30T19:35:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/standard-chemoradiation-outperforms-de-intensified-treatments-in-hpv-associated-news-medical 2024-09-30T19:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/rheumatoid-arthritis-study-ids-macrophages-that-could-hasten-diagnosis-treatment 2024-09-30T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rheumatoid-arthritis-study-ids-macrophages-that-could-hasten-diagnosis-treatment 2024-09-30T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/outpatient-car-t-therapy-shows-promise-for-treating-lymphoma-patients-news-medical 2024-09-30T19:19:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outpatient-car-t-therapy-shows-promise-for-treating-lymphoma-patients-news-medical 2024-09-30T19:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-real-world-data-show-deucravacitinib-efficacious-for-scalp-overall-psoriasis 2024-09-30T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-real-world-data-show-deucravacitinib-efficacious-for-scalp-overall-psoriasis 2024-09-30T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/route-66-spore-grant-to-study-uterine-cancers-unm-health-sciences-center 2024-09-30T18:52:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/route-66-spore-grant-to-study-uterine-cancers-unm-health-sciences-center 2024-09-30T18:52:05+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-beats-6-4-billion-lawsuit-over-delayed-cancer-drug-the-mighty-790-kfgo 2024-09-30T18:43:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-beats-6-4-billion-lawsuit-over-delayed-cancer-drug-the-mighty-790-kfgo 2024-09-30T18:43:39+00:00 weekly 0.7 https://trial.medpath.com/news/pi-cardia-receives-fda-market-clearance-for-shortcuttm-biospace 2024-09-30T18:33:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pi-cardia-receives-fda-market-clearance-for-shortcuttm-biospace 2024-09-30T18:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/walden-biosciences-fully-enrolls-first-cohort-in-phase-2-basket-study-of-wal0921-in-biospace 2024-09-30T18:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/walden-biosciences-fully-enrolls-first-cohort-in-phase-2-basket-study-of-wal0921-in-biospace 2024-09-30T18:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-efficacy-of-endostar-continuous-infusion-combined-with-concurrent-frontiers 2024-09-30T18:01:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-efficacy-of-endostar-continuous-infusion-combined-with-concurrent-frontiers 2024-09-30T18:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/from-the-esmo-congress-2024-nature-reviews-clinical-oncology 2024-09-30T17:52:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/from-the-esmo-congress-2024-nature-reviews-clinical-oncology 2024-09-30T17:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-quality-of-life-in-patients-enrolled-in-a-randomized-clinical-trial-evaluating 2024-09-30T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-quality-of-life-in-patients-enrolled-in-a-randomized-clinical-trial-evaluating 2024-09-30T17:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/2-year-study-affirms-bimekizumab-s-efficacy-in-hidradenitis-suppurativa 2024-09-30T17:21:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-year-study-affirms-bimekizumab-s-efficacy-in-hidradenitis-suppurativa 2024-09-30T17:21:18+00:00 weekly 0.7 https://trial.medpath.com/news/kras-inhibitors-market-new-treatments-are-set-to-change-cancer-care-delveinsight 2024-09-30T17:16:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kras-inhibitors-market-new-treatments-are-set-to-change-cancer-care-delveinsight 2024-09-30T17:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/exploiting-the-role-of-csf-nfl-chit1-and-mir-181b-as-potential-diagnostic-and-prognostic 2024-09-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploiting-the-role-of-csf-nfl-chit1-and-mir-181b-as-potential-diagnostic-and-prognostic 2024-09-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/ocuphire-pharma-releases-results-from-mira-2-and-mira-3-clinical-trials-for-phentolamine 2024-09-30T17:01:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocuphire-pharma-releases-results-from-mira-2-and-mira-3-clinical-trials-for-phentolamine 2024-09-30T17:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-partnering-monthly-update-august-2024-taylor-wessing 2024-09-30T16:55:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-partnering-monthly-update-august-2024-taylor-wessing 2024-09-30T16:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/migraine-drug-could-help-prevent-the-overuse-of-painkillers-miriam-stoppard-the-mirror 2024-09-30T16:47:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/migraine-drug-could-help-prevent-the-overuse-of-painkillers-miriam-stoppard-the-mirror 2024-09-30T16:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/a-multi-center-randomized-double-blind-sham-stimulation-controlled-study-of-transcranial 2024-09-30T16:39:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multi-center-randomized-double-blind-sham-stimulation-controlled-study-of-transcranial 2024-09-30T16:39:29+00:00 weekly 0.7 https://trial.medpath.com/news/prescribing-antipsychotics-in-patients-with-dementia-what-clinicians-should-know 2024-09-30T16:38:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prescribing-antipsychotics-in-patients-with-dementia-what-clinicians-should-know 2024-09-30T16:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/updated-findings-with-belzutifan-in-von-hippel-lindau-disease-associated-cns 2024-09-30T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-findings-with-belzutifan-in-von-hippel-lindau-disease-associated-cns 2024-09-30T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-bladder-preservation-a-modern-choice-for-patients-urotoday 2024-09-30T16:14:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-bladder-preservation-a-modern-choice-for-patients-urotoday 2024-09-30T16:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-100-ketamine-reaches-stability-milestone-contract-pharma 2024-09-30T16:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-100-ketamine-reaches-stability-milestone-contract-pharma 2024-09-30T16:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-strategies-and-evidence-for-sabr-in-rcc-urotoday 2024-09-30T15:57:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-strategies-and-evidence-for-sabr-in-rcc-urotoday 2024-09-30T15:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/screening-for-helicobacter-pylori-to-prevent-gastric-cancer-a-pragmatic-randomized-clinical-trial 2024-09-30T15:56:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/screening-for-helicobacter-pylori-to-prevent-gastric-cancer-a-pragmatic-randomized-clinical-trial 2024-09-30T15:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/lanifibranor-may-promote-liver-gains-seen-in-phase-3-mash-trial 2024-09-30T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lanifibranor-may-promote-liver-gains-seen-in-phase-3-mash-trial 2024-09-30T15:50:34+00:00 weekly 0.7 https://trial.medpath.com/news/nih-fast-track-grant-for-novel-therapeutic-to-treat-glioblastoma-awarded-to-rosalind 2024-09-30T15:47:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-fast-track-grant-for-novel-therapeutic-to-treat-glioblastoma-awarded-to-rosalind 2024-09-30T15:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/mytomorrows-and-curelgmd2i-partnership-to-improve-access-to-clinical-trials-for-limb 2024-09-30T15:43:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mytomorrows-and-curelgmd2i-partnership-to-improve-access-to-clinical-trials-for-limb 2024-09-30T15:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/siemens-healthineers-receives-fda-premarket-approval-for-3d-portion-of-mammography-system 2024-09-30T15:33:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siemens-healthineers-receives-fda-premarket-approval-for-3d-portion-of-mammography-system 2024-09-30T15:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/opinion-goal-is-to-reverse-paralysis-if-washington-doesn-t-get-in-way-hartford-courant 2024-09-30T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opinion-goal-is-to-reverse-paralysis-if-washington-doesn-t-get-in-way-hartford-courant 2024-09-30T15:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-swot-analysis-cns-drug-maker-s-stock-faces-pipeline-hurdles 2024-09-30T15:18:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-therapeutics-swot-analysis-cns-drug-maker-s-stock-faces-pipeline-hurdles 2024-09-30T15:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-hypoxia-on-18f-fluoromisonidazole-positron-emission-tomography-and-distant 2024-09-30T15:18:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-hypoxia-on-18f-fluoromisonidazole-positron-emission-tomography-and-distant 2024-09-30T15:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-2a-data-suggest-disease-modifying-potential-of-cnp-104-in-pbc-hcplive 2024-09-30T15:13:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-2a-data-suggest-disease-modifying-potential-of-cnp-104-in-pbc-hcplive 2024-09-30T15:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/key-reasons-behind-surge-in-semaglutide-usage-european-pharmaceutical-manufacturer 2024-09-30T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-reasons-behind-surge-in-semaglutide-usage-european-pharmaceutical-manufacturer 2024-09-30T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-therapy-trumps-surgery-in-nsclc-debate-cancer-network 2024-09-30T14:52:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-therapy-trumps-surgery-in-nsclc-debate-cancer-network 2024-09-30T14:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/uc-cancer-center-experts-present-research-at-astro-2024-university-of-cincinnati 2024-09-30T14:52:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uc-cancer-center-experts-present-research-at-astro-2024-university-of-cincinnati 2024-09-30T14:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/a-standing-platform-for-cancer-drug-development-using-ctdna-based-evidence-of-recurrence-nature 2024-09-30T14:50:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-standing-platform-for-cancer-drug-development-using-ctdna-based-evidence-of-recurrence-nature 2024-09-30T14:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/arcturus-covid-19-vaccine-triggers-enhanced-immune-response 2024-09-30T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcturus-covid-19-vaccine-triggers-enhanced-immune-response 2024-09-30T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/tenax-therapeutics-inc-initiation-of-research-coverage-william-blair 2024-09-30T14:43:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenax-therapeutics-inc-initiation-of-research-coverage-william-blair 2024-09-30T14:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/the-evolving-treatment-landscape-for-alzheimer-s-technology-networks 2024-09-30T14:42:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-evolving-treatment-landscape-for-alzheimer-s-technology-networks 2024-09-30T14:42:20+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-life-shares-gain-1-today-after-us-fda-approves-cancer-drug-worth-870-million 2024-09-30T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zydus-life-shares-gain-1-today-after-us-fda-approves-cancer-drug-worth-870-million 2024-09-30T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/shorter-course-of-breast-cancer-radiation-won-t-affect-breast-reconstruction 2024-09-30T14:09:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorter-course-of-breast-cancer-radiation-won-t-affect-breast-reconstruction 2024-09-30T14:09:39+00:00 weekly 0.7 https://trial.medpath.com/news/trial-shows-timing-matters-when-adding-immunotherapy-to-chemoradiation-for-limited-stage 2024-09-30T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-shows-timing-matters-when-adding-immunotherapy-to-chemoradiation-for-limited-stage 2024-09-30T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/memed-s-diagnostic-reduces-antibiotic-overuse-in-us-trial-inside-precision-medicine 2024-09-30T13:56:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memed-s-diagnostic-reduces-antibiotic-overuse-in-us-trial-inside-precision-medicine 2024-09-30T13:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/september-30-2024-new-guide-from-nih-collaboratory-promotes-health-equity-in 2024-09-30T13:47:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-30-2024-new-guide-from-nih-collaboratory-promotes-health-equity-in 2024-09-30T13:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-announces-submission-of-supplemental-biologics-license-application-to 2024-09-30T13:34:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-announces-submission-of-supplemental-biologics-license-application-to 2024-09-30T13:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/vaping-addiction-drug-developer-achieve-to-sell-up-to-50-million-of-stock-kursiv-kz 2024-09-30T13:33:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaping-addiction-drug-developer-achieve-to-sell-up-to-50-million-of-stock-kursiv-kz 2024-09-30T13:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/bay-area-surfer-scientologist-and-billionaire-is-tackling-one-of-medicine-s-toughest-problems 2024-09-30T13:19:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bay-area-surfer-scientologist-and-billionaire-is-tackling-one-of-medicine-s-toughest-problems 2024-09-30T13:19:57+00:00 weekly 0.7 https://trial.medpath.com/news/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arctm-system 2024-09-30T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accelerate-diagnostics-announces-fda-clearance-of-its-accelerate-arctm-system 2024-09-30T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/catching-up-with-synchron-s-tom-oxley-on-the-path-to-a-pivotal-trial 2024-09-30T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/catching-up-with-synchron-s-tom-oxley-on-the-path-to-a-pivotal-trial 2024-09-30T13:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-examining-use-of-nalmefene-hci-injection-for-opioid-overdose-reversal-in 2024-09-30T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-examining-use-of-nalmefene-hci-injection-for-opioid-overdose-reversal-in 2024-09-30T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/bioai-arbele-partner-to-advance-predictive-ai-models-in-oncology-clinical-trials 2024-09-30T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioai-arbele-partner-to-advance-predictive-ai-models-in-oncology-clinical-trials 2024-09-30T13:11:17+00:00 weekly 0.7 https://trial.medpath.com/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-and-four 2024-09-30T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-and-four 2024-09-30T13:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life 2024-09-30T13:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-announces-publication-of-positive-health-related-quality-of-life 2024-09-30T13:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease 2024-09-30T13:05:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-completes-enrollment-for-phase-2-trial-in-early-alzheimer-s-disease 2024-09-30T13:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/could-we-prevent-asthma-in-young-allergic-children-boston-children-s-answers 2024-09-30T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-we-prevent-asthma-in-young-allergic-children-boston-children-s-answers 2024-09-30T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-to-support-nih-funded-expanded-access-clinical-globenewswire 2024-09-30T13:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicinova-to-support-nih-funded-expanded-access-clinical-globenewswire 2024-09-30T13:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-pr-newswire 2024-09-30T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mitsubishi-tanabe-pharma-america-presents-open-label-extension-outcomes-and-pr-newswire 2024-09-30T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-prepares-for-phase-ii-trials-for-antiviral-nv-387-nyse-a-nnvc 2024-09-30T13:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-prepares-for-phase-ii-trials-for-antiviral-nv-387-nyse-a-nnvc 2024-09-30T13:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-the-fight-against-superbacteria-by-a-hungarian-research-team 2024-09-30T12:47:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-the-fight-against-superbacteria-by-a-hungarian-research-team 2024-09-30T12:47:42+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-clinical-basic-clinical-research-exploring-novel-immunotargets-for-ovarian-cancer 2024-09-30T12:45:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-clinical-basic-clinical-research-exploring-novel-immunotargets-for-ovarian-cancer 2024-09-30T12:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic 2024-09-30T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-completes-enrollment-in-phase-2b-impact-trial-of-pemvidutide-in-metabolic 2024-09-30T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-announces-positive-phase-2b-topline-clinical-globenewswire 2024-09-30T12:36:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/windtree-announces-positive-phase-2b-topline-clinical-globenewswire 2024-09-30T12:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-3-year-skeletal-dynamics-data-for-adults-with-hypoparathyroidism-treated-with-stock-titan 2024-09-30T12:34:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-3-year-skeletal-dynamics-data-for-adults-with-hypoparathyroidism-treated-with-stock-titan 2024-09-30T12:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury 2024-09-30T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nervgen-pharma-provides-update-on-phase-1b-2a-clinical-trial-of-nvg-291-in-spinal-cord-injury 2024-09-30T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting 2024-09-30T12:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aeon-biopharma-announces-positive-outcome-from-fda-biosimilar-advisory-meeting 2024-09-30T12:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-pooled-analysis-of-two-phase 2024-09-30T12:18:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perfluorohexyloctane-ophthalmic-solution-for-dry-eye-disease-pooled-analysis-of-two-phase 2024-09-30T12:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/precision-biosciences-submits-first-clinical-trial-applications-to-initiate-phase-1-trial-biospace 2024-09-30T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-biosciences-submits-first-clinical-trial-applications-to-initiate-phase-1-trial-biospace 2024-09-30T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-nkt2152-sparks-excitement-in-rcc-amivantamab-chemotherapy 2024-09-30T12:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-nkt2152-sparks-excitement-in-rcc-amivantamab-chemotherapy 2024-09-30T12:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-research-announces-it-has-begun-enrolling-patients-in-aribio-s-phase-3-polaris 2024-09-30T12:16:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-research-announces-it-has-begun-enrolling-patients-in-aribio-s-phase-3-polaris 2024-09-30T12:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-announces-fda-clearance-of-the-globenewswire 2024-09-30T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calidi-biotherapeutics-announces-fda-clearance-of-the-globenewswire 2024-09-30T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its 2024-09-30T12:04:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-1-of-its 2024-09-30T12:04:36+00:00 weekly 0.7 https://trial.medpath.com/news/family-heart-foundation-launches-free-at-home-lipid-screening-program-to-combat-cardiovascular-disease 2024-09-30T12:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/family-heart-foundation-launches-free-at-home-lipid-screening-program-to-combat-cardiovascular-disease 2024-09-30T12:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/dana-farber-cancer-institute-raises-more-than-2-billion-in-record-breaking-fundraising 2024-09-30T11:43:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dana-farber-cancer-institute-raises-more-than-2-billion-in-record-breaking-fundraising 2024-09-30T11:43:22+00:00 weekly 0.7 https://trial.medpath.com/news/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate 2024-09-30T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geneditbio-secures-strategic-investment-from-gobi-partners-gba-to-accelerate 2024-09-30T11:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-completes-enrollment-of-fortify-phase-3-globenewswire 2024-09-30T11:33:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-completes-enrollment-of-fortify-phase-3-globenewswire 2024-09-30T11:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine 2024-09-30T11:32:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-initiates-pivotal-trial-of-novel-investigational-drug-for-treatment-of-migraine 2024-09-30T11:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/national-institutes-of-health-study-finds-no-reliable-biomarkers-exist-for-long-covid 2024-09-30T11:29:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-institutes-of-health-study-finds-no-reliable-biomarkers-exist-for-long-covid 2024-09-30T11:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-announces-first-participant-dosed-in-pivotal-phase-3-trial-of-investigational 2024-09-30T11:17:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-announces-first-participant-dosed-in-pivotal-phase-3-trial-of-investigational 2024-09-30T11:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/2-minute-medicine-rewind-september-30-2024 2024-09-30T11:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-minute-medicine-rewind-september-30-2024 2024-09-30T11:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-october-2024-rttnews 2024-09-30T11:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stocks-facing-fda-decision-in-october-2024-rttnews 2024-09-30T11:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-participation-in-endpoints-globenewswire 2024-09-30T11:01:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-announces-participation-in-endpoints-globenewswire 2024-09-30T11:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/self-management-support-program-delivered-in-the-sub-acute-phase-after-traumatic-injury 2024-09-30T10:39:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/self-management-support-program-delivered-in-the-sub-acute-phase-after-traumatic-injury 2024-09-30T10:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-stock-titan 2024-09-30T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-inc-has-filed-its-annual-report-broad-spectrum-antiviral-nv-387-stock-titan 2024-09-30T10:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-r-pertuzumab 2024-09-30T10:18:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-endpoint-met-in-phase-3-comparative-clinical-study-of-perjeta-r-pertuzumab 2024-09-30T10:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer 2024-09-30T10:14:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer 2024-09-30T10:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaust-limited-issues-new-shares-advances-als-treatment-tipranks-com 2024-09-30T09:34:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaust-limited-issues-new-shares-advances-als-treatment-tipranks-com 2024-09-30T09:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-yuvanci-r-single-tablet-globenewswire 2024-09-30T09:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-yuvanci-r-single-tablet-globenewswire 2024-09-30T09:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/synthetic-thc-may-calm-agitation-in-alzheimer-s-patients 2024-09-30T09:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synthetic-thc-may-calm-agitation-in-alzheimer-s-patients 2024-09-30T09:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/role-of-the-screening-with-coronary-computed-tomography-angiography-on-lipid-trials-journal 2024-09-30T08:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/role-of-the-screening-with-coronary-computed-tomography-angiography-on-lipid-trials-journal 2024-09-30T08:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/a-decade-of-pd-1-inhibitors-keytruda-and-opdivo-transform-global-cancer-treatment-landscape 2024-09-30T07:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-decade-of-pd-1-inhibitors-keytruda-and-opdivo-transform-global-cancer-treatment-landscape 2024-09-30T07:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/medicines-regulators-weigh-hope-and-hype-with-new-alzheimer-s-drugs-swissinfo 2024-09-30T07:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicines-regulators-weigh-hope-and-hype-with-new-alzheimer-s-drugs-swissinfo 2024-09-30T07:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment 2024-09-30T07:19:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment 2024-09-30T07:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/sifi-announces-allowance-of-patent-on-polihexanide-for-europe-and-commercial-launch-of 2024-09-30T07:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sifi-announces-allowance-of-patent-on-polihexanide-for-europe-and-commercial-launch-of 2024-09-30T07:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/identifying-biomarkers-for-treatment-of-uveal-melanoma-by-t-cell-engager-using-a-qsp-model 2024-09-30T06:37:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/identifying-biomarkers-for-treatment-of-uveal-melanoma-by-t-cell-engager-using-a-qsp-model 2024-09-30T06:37:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-solutions-show-promise-in-combating-pharmacist-burnout-and-enhancing-patient-care 2024-09-30T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-solutions-show-promise-in-combating-pharmacist-burnout-and-enhancing-patient-care 2024-09-30T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:24:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:24:27+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:21:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modalis-therapeutics-fda-grants-rare-pediatric-disease-designation-to-mdl-101-for-the 2024-09-30T06:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacokinetics-and-pharmacogenomics-of-ribociclib-in-black-patients-with-metastatic 2024-09-30T06:16:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacokinetics-and-pharmacogenomics-of-ribociclib-in-black-patients-with-metastatic 2024-09-30T06:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age 2024-09-30T06:05:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/photocure-partner-asieris-unveils-cevira-apl-1702-phase-iii-subgroup-analysis-by-age 2024-09-30T06:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-to-present-six-analyses-of-the-phase-3-enhance-studies-in-copd-at-chest-2024 2024-09-30T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-to-present-six-analyses-of-the-phase-3-enhance-studies-in-copd-at-chest-2024 2024-09-30T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-study-3 2024-09-30T06:03:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-study-3 2024-09-30T06:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-completes-imp-manufacturing-for-phase-iii-marketscreener 2024-09-30T05:56:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-completes-imp-manufacturing-for-phase-iii-marketscreener 2024-09-30T05:56:24+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-s-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line 2024-09-30T05:48:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-s-cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line 2024-09-30T05:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/veteran-tennessee-pharmacist-reflects-on-45-years-of-community-service-and-industry-evolution 2024-09-30T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veteran-tennessee-pharmacist-reflects-on-45-years-of-community-service-and-industry-evolution 2024-09-30T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-critical-treatment-gaps-in-metastatic-colorectal-cancer-management 2024-09-30T05:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-highlight-critical-treatment-gaps-in-metastatic-colorectal-cancer-management 2024-09-30T05:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/closer-to-us-commercialisation-ebr-achieves-major-fda-milestone-stockhead 2024-09-30T05:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closer-to-us-commercialisation-ebr-achieves-major-fda-milestone-stockhead 2024-09-30T05:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-healthcare-economics-transforming-clinical-trials-and-value-assessment 2024-09-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-revolutionizes-healthcare-economics-transforming-clinical-trials-and-value-assessment 2024-09-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-biofrontera-bms-and-zealand-biospace 2024-09-30T04:21:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-biofrontera-bms-and-zealand-biospace 2024-09-30T04:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/jeil-pharm-launches-jaqbo-its-1st-in-house-drug-in-korea-s-1-billion-peptic-ulcer-market 2024-09-30T03:57:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jeil-pharm-launches-jaqbo-its-1st-in-house-drug-in-korea-s-1-billion-peptic-ulcer-market 2024-09-30T03:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/duke-nus-study-proposes-new-heart-failure-treatment-targeting-abnormal-hormone-activity 2024-09-30T03:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-nus-study-proposes-new-heart-failure-treatment-targeting-abnormal-hormone-activity 2024-09-30T03:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-completes-toxicology-study-for-avicursen-ahead-of-us-fda-discussions 2024-09-30T02:42:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/percheron-therapeutics-completes-toxicology-study-for-avicursen-ahead-of-us-fda-discussions 2024-09-30T02:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/valerio-therapeutics-expands-antibody-development-capabilities-with-emglev-therapeutics-acquisition 2024-09-30T02:38:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valerio-therapeutics-expands-antibody-development-capabilities-with-emglev-therapeutics-acquisition 2024-09-30T02:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/up-manila-researchers-unveil-promising-ampalaya-tablet-for-type-2-diabetes 2024-09-30T02:07:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/up-manila-researchers-unveil-promising-ampalaya-tablet-for-type-2-diabetes 2024-09-30T02:07:59+00:00 weekly 0.7 https://trial.medpath.com/news/mesoblast-to-raise-50m-from-top-shareholder-for-product-launch-capital-brief 2024-09-30T00:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesoblast-to-raise-50m-from-top-shareholder-for-product-launch-capital-brief 2024-09-30T00:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-completes-phase-ii-trial-tipranks-com 2024-09-30T00:11:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cutia-therapeutics-completes-phase-ii-trial-tipranks-com 2024-09-30T00:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/medidata-clinches-two-excellence-awards-for-innovative-clinical-trial-solutions 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medidata-clinches-two-excellence-awards-for-innovative-clinical-trial-solutions 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-completes-patient-enrollment-in-phase-iib-study-of-pirepemat-for-parkinson-s-disease 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-completes-patient-enrollment-in-phase-iib-study-of-pirepemat-for-parkinson-s-disease 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-fda-approval-of-bizengri-r 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-announces-fda-approval-of-bizengri-r 2024-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/histone-deacetylase-inhibition-enhances-extracellular-vesicles-from-muscle-to-promote 2024-09-29T23:48:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/histone-deacetylase-inhibition-enhances-extracellular-vesicles-from-muscle-to-promote 2024-09-29T23:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/initial-results-of-a-phase-2-trial-of-stereotactic-body-radiation-therapy-hormone-androgen 2024-09-29T23:27:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/initial-results-of-a-phase-2-trial-of-stereotactic-body-radiation-therapy-hormone-androgen 2024-09-29T23:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-adjuvant-radiotherapy-bart-acute-and-late-toxicity-from-a-phase-iii-multicenter 2024-09-29T23:27:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bladder-adjuvant-radiotherapy-bart-acute-and-late-toxicity-from-a-phase-iii-multicenter 2024-09-29T23:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-post-prostatectomy-linac-based-ultrahypofractionated-radiotherapy-for-urotoday 2024-09-29T23:27:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-post-prostatectomy-linac-based-ultrahypofractionated-radiotherapy-for-urotoday 2024-09-29T23:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-integrating-novel-therapeutics-with-trimodal-therapy-tmt-urotoday 2024-09-29T23:27:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-integrating-novel-therapeutics-with-trimodal-therapy-tmt-urotoday 2024-09-29T23:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/astro-2024-the-space-time-continuum-in-metastatic-castration-sensitive-prostate-cancer 2024-09-29T23:27:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astro-2024-the-space-time-continuum-in-metastatic-castration-sensitive-prostate-cancer 2024-09-29T23:27:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-alarm-s-mike-peters-says-it-s-incredible-as-he-issues-huge-cancer-update-the-mirror 2024-09-29T23:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-alarm-s-mike-peters-says-it-s-incredible-as-he-issues-huge-cancer-update-the-mirror 2024-09-29T23:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/potential-of-device-assisted-therapy-for-advanced-stage-parkinson-disease-david-devos-md-phd 2024-09-29T23:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/potential-of-device-assisted-therapy-for-advanced-stage-parkinson-disease-david-devos-md-phd 2024-09-29T23:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/blockchain-technology-emerges-as-key-weapon-against-200b-counterfeit-drug-market 2024-09-29T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blockchain-technology-emerges-as-key-weapon-against-200b-counterfeit-drug-market 2024-09-29T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-who-experience-side-effects-from-cranial-radiation-therapy-may-recover-full 2024-09-29T21:18:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/people-who-experience-side-effects-from-cranial-radiation-therapy-may-recover-full 2024-09-29T21:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/and-high-risk-localized-prostate-cancer-results-from-the-getug-14-randomized-phase-iii-trial 2024-09-29T21:15:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/and-high-risk-localized-prostate-cancer-results-from-the-getug-14-randomized-phase-iii-trial 2024-09-29T21:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/apac-clinical-services-market-set-to-reach-140-billion-by-2031-as-region-emerges-as-trial-powerhouse 2024-09-29T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apac-clinical-services-market-set-to-reach-140-billion-by-2031-as-region-emerges-as-trial-powerhouse 2024-09-29T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pbt-imrt-provide-similar-patient-reported-outcomes-for-prostate-cancer-at-5-years 2024-09-29T19:16:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbt-imrt-provide-similar-patient-reported-outcomes-for-prostate-cancer-at-5-years 2024-09-29T19:16:45+00:00 weekly 0.7 https://trial.medpath.com/news/wall-street-swot-editas-medicine-stock-faces-challenges-in-competitive-gene-editing-market 2024-09-29T17:27:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wall-street-swot-editas-medicine-stock-faces-challenges-in-competitive-gene-editing-market 2024-09-29T17:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharmaceutical-therapy-offers-promise-for-people-with-tough-to-treat-meningioma-brain-tumors 2024-09-29T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharmaceutical-therapy-offers-promise-for-people-with-tough-to-treat-meningioma-brain-tumors 2024-09-29T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-submits-supplemental-new-drug-application-to-usfda-seeking-expanded-indication 2024-09-29T16:56:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-submits-supplemental-new-drug-application-to-usfda-seeking-expanded-indication 2024-09-29T16:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/not-a-placebo-study-finds-meditation-offers-genuine-pain-relief-sciencealert 2024-09-29T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/not-a-placebo-study-finds-meditation-offers-genuine-pain-relief-sciencealert 2024-09-29T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/first-interim-results-from-fine-real-a-prospective-non-interventional-phase-4-study 2024-09-29T15:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-interim-results-from-fine-real-a-prospective-non-interventional-phase-4-study 2024-09-29T15:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/prior-local-therapy-does-not-impact-mcrpc-survival-with-arpi-treatment-urology-times 2024-09-29T14:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prior-local-therapy-does-not-impact-mcrpc-survival-with-arpi-treatment-urology-times 2024-09-29T14:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-presented-comparative-clinical-outcomes-on-the-optimal-lymphodepletion-prior 2024-09-29T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iaso-bio-presented-comparative-clinical-outcomes-on-the-optimal-lymphodepletion-prior 2024-09-29T14:26:47+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-september-23-to-september-27-drug-topics 2024-09-29T14:24:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekend-icymi-september-23-to-september-27-drug-topics 2024-09-29T14:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/lumos-pharma-a-strong-buy-on-innovative-drug-prospects-and-solid-financials 2024-09-29T13:53:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumos-pharma-a-strong-buy-on-innovative-drug-prospects-and-solid-financials 2024-09-29T13:53:59+00:00 weekly 0.7 https://trial.medpath.com/news/avicenna-ai-receives-fda-510-k-clearance-for-cervical-spine-fracture-ai-tool-healio 2024-09-29T13:51:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avicenna-ai-receives-fda-510-k-clearance-for-cervical-spine-fracture-ai-tool-healio 2024-09-29T13:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-highlights-new-data-from-helios-b-study-of-vutrisiran-for-the-treatment-of-quantisnow 2024-09-29T13:18:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-highlights-new-data-from-helios-b-study-of-vutrisiran-for-the-treatment-of-quantisnow 2024-09-29T13:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/world-heart-day-2024-looking-back-at-cardiology-s-year-of-progress-in-cell-and-gene-therapy 2024-09-29T13:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-heart-day-2024-looking-back-at-cardiology-s-year-of-progress-in-cell-and-gene-therapy 2024-09-29T13:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-early-tracking-of-childhood-health-determinants-etched 2024-09-29T12:24:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-protocol-for-early-tracking-of-childhood-health-determinants-etched 2024-09-29T12:24:15+00:00 weekly 0.7 https://trial.medpath.com/news/is-merck-stock-a-buy-the-globe-and-mail 2024-09-29T11:38:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-merck-stock-a-buy-the-globe-and-mail 2024-09-29T11:38:04+00:00 weekly 0.7 https://trial.medpath.com/news/858-therapeutics-drug-discovery-company-raises-50-million-series-b-pulse-2-0 2024-09-29T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/858-therapeutics-drug-discovery-company-raises-50-million-series-b-pulse-2-0 2024-09-29T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-tenofovir-alafenamide-fumarate-on-serum-lipid-profiles-in-patients-with-chronic-hepatitis-b 2024-09-29T10:31:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-tenofovir-alafenamide-fumarate-on-serum-lipid-profiles-in-patients-with-chronic-hepatitis-b 2024-09-29T10:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/2020-acr-guidelines-challenge-traditional-gout-management-in-chronic-kidney-disease-patients 2024-09-29T10:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2020-acr-guidelines-challenge-traditional-gout-management-in-chronic-kidney-disease-patients 2024-09-29T10:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/discussing-interim-findings-on-nemolizumab-for-atopic-dermatitis-with-diamant-thaci-md 2024-09-29T08:02:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/discussing-interim-findings-on-nemolizumab-for-atopic-dermatitis-with-diamant-thaci-md 2024-09-29T08:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/shingrix-vaccine-shows-strong-protection-against-shingles-in-ibd-patients-mayo-clinic-study-finds 2024-09-29T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shingrix-vaccine-shows-strong-protection-against-shingles-in-ibd-patients-mayo-clinic-study-finds 2024-09-29T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/post-transplant-cyclophosphamide-breakthrough-expands-donor-pool-for-all-patients 2024-09-29T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-transplant-cyclophosphamide-breakthrough-expands-donor-pool-for-all-patients 2024-09-29T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/delavirdine-gains-approval-as-second-nnrti-for-anti-hiv-combination-regimens-pubmed 2024-09-29T05:45:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delavirdine-gains-approval-as-second-nnrti-for-anti-hiv-combination-regimens-pubmed 2024-09-29T05:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-primary-tumor-metastasized-lesions-linked-to-improved-5-year-omhspc-survival 2024-09-29T05:24:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-primary-tumor-metastasized-lesions-linked-to-improved-5-year-omhspc-survival 2024-09-29T05:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/ga-68-psma-11-tracer-could-guide-scintix-radiation-therapy-for-metastasized-prostate-cancer 2024-09-29T04:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ga-68-psma-11-tracer-could-guide-scintix-radiation-therapy-for-metastasized-prostate-cancer 2024-09-29T04:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/abos-acumen-pharmaceuticals-inc-latest-stock-news-market-updates 2024-09-29T03:16:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abos-acumen-pharmaceuticals-inc-latest-stock-news-market-updates 2024-09-29T03:16:56+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-itt 2024-09-29T02:25:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-outcomes-of-patients-treated-with-ribociclib-in-combination-w-itt 2024-09-29T02:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/virologic-suppression-rate-and-associated-factors-for-third-line-hiv-treatment-in-addis-ababa 2024-09-29T00:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virologic-suppression-rate-and-associated-factors-for-third-line-hiv-treatment-in-addis-ababa 2024-09-29T00:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-comparison-of-efficacy-of-erector-spinae-plane-block-versus-serratus-anterior-trials-journal 2024-09-28T23:37:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-comparison-of-efficacy-of-erector-spinae-plane-block-versus-serratus-anterior-trials-journal 2024-09-28T23:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/a-synuclein-antibody-lu-af82422-shows-disease-modifying-potential-in-phase-2-amulet 2024-09-28T22:56:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-synuclein-antibody-lu-af82422-shows-disease-modifying-potential-in-phase-2-amulet 2024-09-28T22:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-lenalidomide-demonstrates-strong-efficacy-tolerability-in-smoldering-multiple-myeloma 2024-09-28T22:10:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/isatuximab-lenalidomide-demonstrates-strong-efficacy-tolerability-in-smoldering-multiple-myeloma 2024-09-28T22:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/stress-confirmed-as-trigger-for-psoriasis-relapse-mcknight-s-long-term-care-news 2024-09-28T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stress-confirmed-as-trigger-for-psoriasis-relapse-mcknight-s-long-term-care-news 2024-09-28T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-endovascular-therapy-for-stroke-patients-mcknight-s-long-term-care-news 2024-09-28T21:35:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-endovascular-therapy-for-stroke-patients-mcknight-s-long-term-care-news 2024-09-28T21:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-for-a-cluster-randomized-controlled-community-effectiveness-trial-of-the 2024-09-28T21:31:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-protocol-for-a-cluster-randomized-controlled-community-effectiveness-trial-of-the 2024-09-28T21:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/bgne-beigene-ltd-american-depositary-shares-latest-stock-news-market-updates 2024-09-28T21:18:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bgne-beigene-ltd-american-depositary-shares-latest-stock-news-market-updates 2024-09-28T21:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/nurses-talk-aes-interstitial-lung-disease-before-treating-with-t-dxd 2024-09-28T21:00:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurses-talk-aes-interstitial-lung-disease-before-treating-with-t-dxd 2024-09-28T21:00:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-nvision-s-3d-printed-peek-interbody-system-voxelmatters 2024-09-28T20:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-nvision-s-3d-printed-peek-interbody-system-voxelmatters 2024-09-28T20:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/structural-basis-for-the-rescue-of-hyperexcitable-cells-by-the-amyotrophic-lateral-sclerosis 2024-09-28T19:58:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/structural-basis-for-the-rescue-of-hyperexcitable-cells-by-the-amyotrophic-lateral-sclerosis 2024-09-28T19:58:01+00:00 weekly 0.7